

CAPTOR THERAPEUTICS S.A. GROUP

CONSOLIDATED FINANCIAL STATEMENT FOR 2022

**April 6, 2023
Wrocław**

CONSOLIDATED STATEMENT OF PERFORMANCE AND OTHER COMPREHENSIVE INCOME	5
CONSOLIDATED STATEMENT OF FINANCIAL POSITION	6
CONSOLIDATED STATEMENT OF CASH FLOWS	7
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY	8
GENERAL INFORMATION	9
1. Information about the Group	9
2. Description of the Capital Group of Captor Therapeutics S.A.	9
3. Composition of the Management Board and Supervisory Board of the Parent Company	9
4. Approval of the consolidated financial statement	10
5. Basis for the preparation of the consolidated financial statement	10
6. Reporting period and comparative figures	10
7. Consolidation basis	10
8. Functional currency and currency of the financial statements	11
9. Transactions in foreign currency	11
10. Correction of an error	12
11. Change in estimates	12
12. New standards and interpretations	12
13. Business continuity	12
ACCOUNTING PRINCIPLES (POLICY) AND ADDITIONAL INFORMATION	14
14. Significant values based on professional judgement and estimates	14
14.1 Professional judgment	14
14.2 Estimation uncertainty	17
15. Important accounting principles	17
15.1 Consolidation principles	17
15.2 Tangible fixed assets	18
15.3 Intangible assets	19
15.4 Leasing	20
15.5 Impairment of non-financial fixed assets	21
15.6 Borrowing costs	22
15.7 Financial assets	22
15.8 Impairment of financial assets	23
15.9 Trade and other receivables	23
15.10 Cash and cash equivalents	23
15.11 Interest-bearing bank loans, borrowings and debt securities	23
15.12 Trade and other payables	24
15.13 Provisions	24
15.14 Retirement and jubilee bonuses	24
15.15 Distribution of profit to staff and special funds	24
15.16 Grants	24
15.17 Revenues	26
15.18 Taxes	26
15.19 Net earnings per share	27
15.20 Equity	27
15.21 Employee share ownership programme – share-based payments	27
15.22 Other assets and liabilities	28
15.23 Information on business segments	28
15.24 Financial income and costs	29
SELECTED EXPLANATORY NOTES TO THE CONSOLIDATED FINANCIAL STATEMENT	30
16. Total revenues	30
17. Costs by type	30

17.1	Operating expenses	30
17.2	Depreciation and amortisation expenses included in the result	31
17.3	Employee benefit costs.....	32
18.	Other operating income and expenses.....	32
19.	Financial income and costs.....	33
20.	Income tax	33
20.1	Tax expense	33
20.2	Reconciliation of the effective income tax rate	33
20.3	Deferred income taxe.....	33
21.	Discontinued operations.....	34
22.	Earnings per share	34
23.	Proposed profit distribution (coverage of loss) for the fiscal year.....	34
24.	Dividends paid and proposed to be paid	34
25.	Expenditures on development work (in progress).....	34
26.	Tangible fixed assets.....	34
27.	Intangible assets	36
28.	Mergers of business entities, acquisitions of assets of significant value and acquisition of minority interests	37
29.	Other non-current assets.....	38
30.	Trade and other receivables.....	38
31.	Other financial assets.....	38
32.	Other assets	39
33.	Cash and cash equivalents.....	39
34.	Equity	39
34.1	Share capital	39
34.1.1	Nominal value of shares	40
34.1.2	Shareholder's rights.....	40
34.1.3	Shareholders with significant shareholding.....	40
34.2	Share premium reserve	41
34.3	Reserve capital.....	41
34.4	Share-based payment reserve	41
35.	Retirement benefit obligations and provisions for liabilities.....	41
36.	Loans received	42
37.	Lease liabilities.....	43
38.	Trade and other liabilities (short-term)	43
39.	Other liabilities/deferred income.....	43
40.	Contingent liabilities	44
41.	Litigation	44
42.	Tax settlements	44
43.	Explanations to the cash flow statement.....	45
44.	Information on related parties	45
44.1	Parent company of the entire Group.....	46
44.2	Entity having a significant influence of the Group	46
45.	Salaries, bonuses and benefits for members of governing bodies	46
45.1	Participation of senior management (including members of the Management Board and Supervisory Board) in the employee share programme	46
46.	Auditor firm's fee.....	47
47.	Purposes and principles of financial risk management.....	47
47.1	Interest rate risk	47
47.2	Foreign exchange risk	48
47.3	Risk related to prices of products and goods.....	48
47.4	Credit risk.....	48
47.5	Risk related to liquidity	48

48.	Financial instruments.....	48
49.	Security instruments established on assets.....	49
50.	Equity management.....	49
51.	Structure of employment	50
52.	Seasonality.....	50
53.	Events after the balance sheet date	50
54.	COVID-19 pandemic.....	51
55.	War in Ukraine.....	51

CONSOLIDATED STATEMENT OF PERFORMANCE AND OTHER COMPREHENSIVE INCOME

CONSOLIDATED STATEMENT OF PERFORMANCE AND OTHER COMPREHENSIVE INCOME	Note	01.01.2022 - 31.12.2022	01.01.2021 - 31.12.2021
CONTINUING OPERATIONS			
Research and development income	16	9,158	3,986
Cost of services sold		2,087	741
Gross profit (loss) on sales		7,071	3,245
Subsidy revenues	16	20,577	21,949
Research and development expenditures	17	44,155	23,115
Project overheads	17	4,510	11,133
General administrative expenses	17	19,558	19,545
Other operating income	18	2,269	2,694
Other operating costs	18	58	5,804
Operating profit (loss)		-38,364	-31,709
Financial income	19	3,127	-
Financial expenses	19	657	863
Profit (loss) from continuing operations before tax		-35,894	-32,572
Income tax	20	-	-
Net profit (loss) from continuing operations		-35,894	-32,572
Net profit (loss) from discontinued operations		-	-
Net profit (loss) for period		-35,894	-32,572
- attributable to shareholders of the parent company		-35,894	-32,572
- attributable to non-controlling interests		-	-
Other comprehensive income			
Items that can be transferred to the result in the subsequent reporting periods		5	4
Foreign exchange differences on translation of foreign units		5	4
Items that may be transferred to the result in subsequent reporting periods		-	38
Actuarial gains/losses		-	38
Other net comprehensive income		5	42
Total comprehensive income		-35,889	-32,530
- attributable to shareholders of the parent company		-35,889	-32,530
- attributable to non-controlling shareholders		-	-
Earnings (loss) per share (in PLN)		-8.61	-7.89
Diluted earnings (loss) per share (in PLN)		-8.24	-7.48

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

CONSOLIDATED STATEMENT OF FINANCIAL POSITION			
ASSETS	Note	31.12.2022	31.12.2021
I. NON-CURRENT ASSETS		11,676	12,986
Expenditure on development work (in progress)	25	180	180
Property, plant and equipment	26	10,666	12,612
Intangible assets	27	602	180
Other non-current assets	29	228	14
II. CURRENT ASSETS		101,324	130,555
Trade and other receivables	30	9,678	11,706
Other financial assets	31	19,854	-
Prepayments and accrued income	32	756	906
Cash and cash equivalents	33	71,036	117,943
TOTAL ASSETS		113,000	143,541
EQUITY AND LIABILITIES	Note	31.12.2022	31.12.2021
I. EQUITY		96,322	124,201
Share capital	34.1	417	413
Share premium reserve	34.2	170,031	170,031
Other capital reserves	34.3	175	175
Share based payment reserve	34.4	19,785	11,779
Retained earnings/Accumulated losses		-94,102	-58,208
Exchange rate differences from the conversion		16	11
Non-controlling interests		-	-
TOTAL LIABILITIES		16,678	19,340
II. NON CURRENT LIABILITIES		3,286	2,973
Pension benefit obligations	35	51	33
Interest-bearing borrowings	36	-	-
Lease liabilities	37	3,235	2,940
III. CURRENT LIABILITIES		13,392	16,367
Trade and other payables	38	7,816	4,738
Lease liabilities	37	3,717	5,241
Provisions for liabilities	35	1,733	6,262
Other liabilities/deferred income	39	126	126
TOTAL EQUITY AND LIABILITIES		113,000	143,541

CONSOLIDATED STATEMENT OF CASH FLOWS

	01.01.2022	01.01.2021
CONSOLIDATED STATEMENT OF CASH FLOWS	-	-
	31.12.2022	31.12.2021
OPERATING ACTIVITIES		
Profit (loss) before tax	-35,894	-32,572
Adjustments:	12,946	4,099
Depreciation	7,094	7,355
Foreign exchange(gains) losses	-111	36
Interest	-2,574	409
Management options programme	8,006	9,495
Change in receivables	1,529	-9,876
Change in liabilities, excluding loans and borrowings	3,364	-8,788
Change in provisions	-4,512	5,536
Change in accruals	150	-68
Net cash flow from operating activities	-22,948	-28,473
INVESTING ACTIVITIES		
I. Inflows	36,801	-
Interest	2,929	-
Bond proceeds	33,872	-
II. Outflows	54,431	5,113
Expenditure on tangible and intangible fixed assets	892	5,113
Purchase of bonds	53,539	-
Net cash flow from investing activities	-17,630	-5,113
FINANCING ACTIVITIES		
I. Inflows	4	148,240
Proceeds from issue of shares	4	148,240
II. Outflows	6,333	7,365
Expenditures on borrowings	-	209
Interest and commission expenses	575	409
Payments of liabilities under lease agreements	5,758	6,747
Net cash flow from financing activities	-6,329	140,875
Total cash flows	-46,907	107,289
Balance sheet change in cash and cash equivalents	-46,907	107,289
Cash at the beginning of period	117,943	10,654
Cash at the end of period	71,036	117,943
- restricted cash	-	-

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY	Share capital	Share premium reserve	Other capital reserves	Share-based payment reserve	Retained earnings/accumulated losses	Exchange rate differences from the conversion	Equity attributable to Parent Company	Non-controlling interests	Total equity
As of 01.01.2022	413	170,031	175	11,779	-58,208	11	124,201	-	124,201
Profit/loss for period	-	-	-	-	-35,894	-	-35,894	-	-35,894
Other comprehensive income	-	-	-	-	-	5	5	-	5
Total comprehensive income for the period	-	-	-	-	-35,894	5	-35,889	-	-35,889
Issue of shares	4	-	-	-	-	-	4	-	4
Share redemption	-	-	-	-	-	-	-	-	-
Management options programme	-	-	-	8,006	-	-	8,006	-	8,006
As of 31.12.2022	417	170,031	175	19,785	-94,102	16	96,322	-	96,322
As of 01.01.2021	359	16,292	5,690	2,284	-25,636	7	-1,004	-	-1,004
Profit/loss for period	-	-	-	-	-32,572	-	-32,572	-	-32,572
Other comprehensive income	-	-	38	-	-	4	42	-	42
Total comprehensive income for the period	-	-	38	-	-32,572	4	-32,530	-	-32,530
Issue of shares	102	153,739	-5,601	-	-	-	148,240	-	148,240
Share redemption	-48	-	48	-	-	-	-	-	-
Management options programme	-	-	-	9,495	-	-	9,495	-	9,495
As of 31.12.2021	413	170,031	175	11,779	-58,208	11	124,201	-	124,201

GENERAL INFORMATION

1. Information about the Group

Captor Therapeutics S.A. (the "Company", "Entity", "Parent Company", "Issuer") was entered in the National Court Register in Poland on 30 December 2015 as a limited liability company under KRS No. 0000594615 and was subsequently transformed into a joint stock company.

The transformation of Captor Therapeutics Sp. z o.o. into Captor Therapeutics S.A. took place pursuant to Article 551 of the Commercial Companies Code, based on the Resolution of the Extraordinary Meeting of Shareholders of Captor Therapeutics Sp. z o.o. of 28 August 2018, covered by notarial deed Rep. A no. 6456/2018, drawn up by Małgorzata Kieruzal – Rydzewska, notary public of the Notary Office in Warsaw, ul. Pańska 98/1.

The Company was assigned statistical number REGON 363381765 and tax identification number NIP 8943071259. The Parent Company has registration number KRS 0000756383.

The Parent Company's registered office is located at 11 Duńska Street in Wrocław.

There have been no changes in the name of the Entity or any other identification data of the Entity since the end of the previous reporting period.

The predominant activity of the Parent Company is scientific research and development in the field of biotechnology (72.11.Z).

As of 19 April 2021, the Issuer's shares are listed on the main market of the Warsaw Stock Exchange.

The Company holds shares in one subsidiary, Captor Therapeutics GmbH based in Switzerland (the "Subsidiary"). The Subsidiary was established by the Company through payment of the share capital of CHF 20,000.

The address of the registered office of the Subsidiary: Hegenheimermattweg 167A, 4123 Allschwil (Basel), Switzerland (previously Gewerbestrasse 24, 4123 Allschwil (Basel), Switzerland).

Date of registration of the Subsidiary: 30 August 2018

The objects of Captor Therapeutics GmbH consist of research and development and the implementation of related projects as well as business development advisory services.

The composition of the Management Board of the Subsidiary as of the balance sheet date and as of the date of this consolidated financial statement: Michał Walczak - President of the Management Board, Sylvain Cottens - Member of the Management Board.

2. Description of the Capital Group of Captor Therapeutics S.A.

The Captor Therapeutics S.A. Capital Group ("Capital Group", "Group") consists of:

- the Parent Company, Captor Therapeutics S.A., based in Wrocław, Poland,
- the Subsidiary, Captor Therapeutics GmbH with its registered office in Allschwil (Basel), Switzerland.

Captor Therapeutics S.A. holds 100% of the shares in the Subsidiary.

Captor Therapeutics S.A. is the ultimate parent company.

Acquisitions/disposals of shares in companies

Apart from the establishment of the Subsidiary in 2018, there were no acquisitions or disposals of shares in subsidiaries.

Changes in the composition of the Group after the balance sheet date

There were no changes in the composition of the Group after the balance sheet date, i.e. in the period from 1 January 2023.

3. Composition of the Management Board and Supervisory Board of the Parent Company

In addition to the General Meeting, the governing bodies of the Entity are as follows: the Management Board and the Supervisory Board.

As of the date of this report, the composition of the Parent Company's Management Board is as follows:

1. Thomas Shepherd - President of the Management Board
2. Michał Walczak - Member of the Management Board, Scientific Director
3. Radosław Krawczyk - Member of the Management Board, Chief Financial Officer

If the Management Board consists of more than one person, the Company shall be represented by one Management Board

Member. If the Management Board consists of more than one person, the Company shall be represented by two Management Board Members acting jointly.

As of 31 December 2022, and as of the date of this consolidated financial statement, the composition of the Parent Company's Supervisory Board is as follows:

1. Paweł Holstinghausen Holsten - Chairman of the Supervisory Board
2. Maciej Wróblewski - Member of the Supervisory Board
3. Florent Gros - Member of the Supervisory Board
4. Krzysztof Samotij - Member of the Supervisory Board
5. Robert Florczykowski – Member of the Management Board

Compared to the composition of the Supervisory Board as of December 31, 2021, there was one change. On 5 January 2022, Robert Florczykowski was appointed a member of the Supervisory Board.

The Company has an Audit Committee appointed by the Supervisory Board on 29 June 2020. As of the date of this consolidated financial statement, the composition of the Audit Committee is as follows:

1. Krzysztof Samotij - Chairman of the Audit Committee
2. Maciej Wróblewski - Member of the Audit Committee
3. Florent Gros - Member of the Audit Committee

The Company has a Remuneration Committee, which was appointed by the Supervisory Board on 7 February 2020. As of the date of this consolidated financial statement, the composition of the Remuneration Committee is as follows:

1. Paweł Holstinghausen Holsten - Chairman of the Remuneration Committee
2. Florent Gros - Member of the Remuneration Committee
3. Robert Florczykowski - Member of the Remuneration Committee

The General Meeting of Shareholders, the Supervisory Board and the Management Board have standard powers arising from the Commercial Companies Code, provided for with respect to joint stock companies, and from the Company's Statute.

4. Approval of the consolidated financial statement

This consolidated financial statement of Captor Therapeutics S.A. was approved by the Management Board of the Parent Company on 6 April 2023.

5. Basis for the preparation of the consolidated financial statement

This consolidated financial statement of the Group has been prepared in accordance with the historical cost principle, except for those financial instruments that are measured at fair value. This consolidated financial statement has been prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the EU.

Taking into account the ongoing process of introducing IFRS standards in the EU and the Group's activities, there is no difference in the accounting principles applied by the Group between IFRS standards that have come into force and IFRS standards approved by the EU. IAS and IFRS include standards and interpretations accepted by the International Accounting Standards Board ("IASB") and the International Financial Reporting Interpretations Committee ("IFRIC").

6. Reporting period and comparative figures

The period covered by this consolidated financial statement comprises the 12-month period ended 31 December 2022 and data as at that date.

The consolidated statement of profit or loss and other comprehensive income, the consolidated statement of cash flows and the consolidated statement of changes in equity cover the consolidated data for the period of 12 months ended 31 December 2022 and comparative data for the period of 12 months ended 31 December 2021. The consolidated statement of financial position includes the consolidated data as of 31 December 2022 and comparative data as of 31 December 2021.

7. Consolidation basis

The Group applies the full consolidation method to its subsidiaries.

This method consists in summing up, in full, the individual items of the respective financial statements of the Parent Company and the Subsidiary and making exclusions (in accordance with IFRS 3): the value, expressed in the purchase price, of the shares of the Parent Company and other units consolidated in the subsidiaries with the part of the net assets of the subsidiaries (measured at fair value) that corresponds to the share of such units in the subsidiaries as at the date of commencement of control over them. The excess of the value of the shares over the corresponding part of the assets is equivalent to the recognition of goodwill in the

consolidated statement of financial position. Otherwise (a negative difference) is written off to profit or loss for the period.

The consolidated statement of profit or loss and other comprehensive income was prepared using the calculation basis. The consolidated statement of cash flows was prepared using the indirect method.

The consolidated financial statements have been presented in thousand PLN unless otherwise indicated. The Subsidiary provides financial statement in its local currency (CHF) and this is translated into PLN at appropriate exchange rates.

The statements of the Subsidiary are prepared for the same reporting period as those of the Parent Company.

8. Functional currency and currency of the financial statements

The functional currency of the Parent Company is the Polish zloty (PLN).

The functional currency of the Subsidiary included in this consolidated financial statement is the Swiss franc (CHF).

The reporting currency of the entire Group is the Polish zloty (PLN).

The functional currency of the entities is considered to be the currency in which the entity generates and spends most of its cash.

9. Transactions in foreign currency

Transactions denominated in foreign currencies are converted as at their initial recognition into the functional currency:

- at the actual rate applied, i.e. the purchase or selling rate applied by the bank in which the transaction is effected, in the case of transactions involving the sale or purchase of currencies and the payment of receivables or payables, or at the rate resulting from agreements concluded with the bank serving the entity or agreed upon through negotiations,
- at the average exchange rate for a given currency set by the NBP as of the transaction date for other transactions. The exchange rate in force at the date of the transaction is the average NBP exchange rate announced on the last working day preceding the conclusion of the transaction.

At the end of each reporting period:

- monetary items expressed in a foreign currency are translated using the closing rate prevailing on that date, i.e. the average rate set for that currency by the NBP,
- non-cash items measured at historical cost in a foreign currency are translated using the exchange rate (i.e. the average NBP exchange rate set for the currency) in effect on the transaction date, and
- non-cash items measured at fair value in a foreign currency are translated using the exchange rate (i.e. the average NBP exchange rate set for the currency) at the date the fair value is determined.

Foreign exchange gains and losses resulting from:

- settlement of transactions in a foreign currency,
- balance sheet valuation of monetary assets and liabilities other than derivatives denominated in foreign currencies are recognised as financial income or expenses.

At the balance sheet date, the assets and liabilities of foreign subsidiaries whose functional currency is a currency other than the Polish zloty are translated into the Group's presentation currency at the exchange rate prevailing at the balance sheet date, and their income statements are translated at exchange rates representing the arithmetic mean of the average exchange rates set by the National Bank of Poland on the last day of each completed month. The exchange differences arising from such translation are recognised directly in equity as a separate component. Upon disposal of a foreign operation, the cumulative deferred exchange differences recognised in equity relating to the foreign operation are recognised in the result.

The following exchange rates were adopted for balance sheet valuation purposes:

exchange rates applied in the financial statements	2022		2021	
	January - December		January - December	
	EUR	CHF	EUR	CHF
exchange rate at the end of the reporting period	4.6899	4.7679	4.5994	4.4484
average exchange rate during the reporting period	4.6883	4.6832	4.5775	4.2416

10. Correction of an error

No correction of prior period errors has been made in this consolidated financial statement.

11. Change in estimates

There has been no change in estimation methods in the period of 12 months ended on 31 December 2022 that would affect the current period or future periods.

12. New standards and interpretations

Impact of new and amended standards and interpretations on the consolidated financial statements of the Group

The following are new or amended IFRS/IFRS regulations and IFRIC interpretations that have been adopted in the EU for use and that the Group has applied since 1 January 2022:

- *IFRS 17 Insurance Contracts (published on May 18, 2017) including amendments to IFRS 17 (published on June 25, 2020) - applicable to reporting periods beginning on or after January 1, 2023,*
- *Amendments to IAS 1 Presentation of financial statements and IFRS Code of Practice 2: Disclosure of accounting policies (published on February 12, 2021) - effective for reporting periods beginning on or after January 1, 2023,*
- *Amendments to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (issued February 12, 2021) - effective for reporting periods beginning on or after January 1, 2023,*
- *Amendments to IAS 12 Income Taxes: Deferred Tax on Assets and Liabilities Arising from a Single Transaction (issued May 7, 2021) - effective for reporting periods beginning on or after January 1, 2023,*
- *Amendments to IFRS 17 Insurance Contracts: Preliminary Application of IFRS 17 and IFRS 9 - Comparative Information (published December 9, 2021) - effective for reporting periods beginning on or after January 1, 2023.*

The following standards and interpretations have been issued by the International Accounting Standards Board and have not been endorsed by the EU:

- *Amendments to IAS 1 Presentation of Financial Statements:*
 - *Classification of liabilities as current or non-current Date (issued on January 23, 2020);*
 - *Classification of liabilities as current or non-current - deferral, effective date (issued July 15, 2020) and*
 - *Long-term liabilities subject to covenants (issued October 31, 2022), applicable to reporting periods beginning on or after January 1, 2024.*
- *Amendments to IFRS 16 Leases: Lease liability in sale and leaseback transactions (published September 22, 2022) - effective for reporting periods beginning on or after January 1, 2024.*

The effective dates are those resulting from the content of the standards promulgated by the International Financial Reporting Council. The application dates of the standards in the European Union may differ from the application dates resulting from the content of the standards and are announced at the time of approval for application by the European Union.

In the opinion of the Parent's Management Board, the above changes will not have a material impact on the consolidated financial statement.

13. Business continuity

This consolidated financial statement of the Group has been prepared on the assumption that the Group will continue as a going concern in the foreseeable future, for at least 12 months after the balance sheet date.

The parent company is a biopharmaceutical firm specializing in the development of drugs that induce targeted degradation of pathogenic proteins. The company is active in the area of cancer and autoimmune diseases for which there are currently no treatment options, or the available methods show significant therapeutic limitations. The parent company is in the early stages of ongoing research. The Group's ability to generate profits from the sale of drugs or the licensing of therapeutic solutions will depend on the success in developing drug candidates and the eventual commercialization of drugs. The target group will be large pharmaceutical firms developing and implementing new drugs based on drug candidates. The Company mainly plans to sell licenses for the results of its projects to firms that, based on their experience and operational potential, will conduct further phases of clinical trials, develop production and launch the drug on the Polish and foreign markets. In addition, the Group will seek to attract partners from the pharmaceutical industry to jointly develop drug candidates not currently in the research or design phase.

Given the peculiarities of the operations of the Group's entities described above and the early stage of the studies being conducted, the Group is currently incurring losses from operations and this situation is expected to continue for the foreseeable future.

However, in the past 12 months, the Group has pursued its strategy and made progress in its ongoing projects, reaching significant milestones in the CT-01 and CT-03 projects in particular, as communicated by the Parent Company in accordance with applicable regulations. In addition, already after the balance sheet date, the Parent Company announced the next steps in its strategy for 2023-2025, in the following areas:

- Clinical Development;
- Collaborate on R&D and development of early-stage projects;
- Strengthening the Optigrade™ platform through its continued development and collaboration with partners;
- Entering global capital markets.

Despite the early stage of the research being conducted, the Group is also recognising revenue from the implementation of partnership agreements. In 2021, the Parent Company launched a project in cooperation with Heptares Therapeutics Ltd (an entity of the Sosei Heptares group) and in the fourth quarter of 2022 another agreement was signed with Ono Pharmaceutical Co., Ltd. The Group recognising total revenues of PLN 9.2 million in 2022 from these agreements.

In 2020, the Parent Company worked on preparing a prospectus and listing the Parent Company's shares on the Warsaw Stock Exchange. As a result of the series G share offering in April 2021, the Parent Company's equity increased by approximately PLN 149.9 million in the first half of 2021. Raising cash from investors changed the financial situation dramatically. Thanks to the funds raised from the IPO and the funds from the NCBiR, the Group is assured of financing for further development and uninterrupted research on its projects over the next time horizon. In addition, the Parent Company has become a reliable partner for its service providers and for financial institutions, which will put the Parent Company in a stronger position in business negotiations in the future.

In view of the epidemic emergency in Poland and the WHO (World Health Organization) announcement of the SARS-CoV-2 coronavirus pandemic worldwide, the Parent Company's Management Board is taking measures to minimize the risk of delaying research and development work. As of the date of this consolidated financial statement, this work is proceeding without major disruptions, in accordance with planned schedules. There have been no significant delays in the delivery of components, materials, machinery and equipment. However, it cannot be ruled out that such delays may occur in the future. No less during the reporting period, there were no events affecting the framework work schedules of the Company and the Group.

Due to the outbreak of conflict between Ukraine and Russia, the Parent Company's Management Board analyzed the impact of the current situation on the Group's operations. In the opinion of the Parent Company's Management Board, there are no significant risks that could significantly affect its operations. The Group has both no assets in Ukraine and no operations in conflict areas.

Taking into account the stable liquidity situation, the level of available funds together with the granted and unused NCBiR co-financing in the total amount of approximately PLN 160 million as of December 31, 2022, and the implementation of the assumed strategy by achieving progress in scientific research, particularly in the CT-01 and CT-03 project, in the opinion of the Parent Company's Management Board, as of 31 December 2022, there is no risk of the continuation of operations by the Capital Group and Group entities.

ACCOUNTING PRINCIPLES (POLICY) AND ADDITIONAL INFORMATION

14. Significant values based on professional judgement and estimates

14.1 Professional judgment

In the process of applying the Group's accounting policies to the matters set out below, the management's professional judgement, in addition to accounting estimates, was of the greatest importance.

Recognition of revenue

The Group recognises revenue when the performance obligation is satisfied (or in the process of being satisfied) by transferring the promised good or service (i.e. the asset) to the customer (the customer obtains control of the asset). Revenue is recognised as amounts equal to the transaction price that has been allocated to the performance obligation.

The Group transfers control of the good or service over time and thereby satisfies the performance obligation and recognises revenue over time when one of the following conditions is met:

- the customer simultaneously receives and take advantage from the benefit as the benefit is being provided,
- as a result of the performance an asset is created or improved and the customer has control of the asset as it arises or is improved,
- the service does not create an asset with an alternative use to the Group and the Group has an enforceable right to payment for the service already rendered.

In applying accounting policies, management makes estimates, judgements and assumptions about the recognition of sales revenue. These estimates are based on past experience, management's expectations or other factors considered relevant.

Research and development

Research expenditure is an innovative and planned search for solutions conceived with the intention of acquiring and assimilating new scientific and technical knowledge. They are:

- activities aimed at acquiring new knowledge;
- the search for, evaluation and final selection of the use of results of research work or other knowledge;
- the search for alternative materials, devices, products, processes, systems or services;
- the formulation, design, evaluation and final selection of new or improved materials, devices, products, processes, systems or services.

The Group recognises research expenditure as an expense as it is incurred. They are therefore part of the result.

The Group recognises development expenditure when it meets, among other things, the following conditions (IAS 38, paragraph 57):

- it is technically possible to complete the intangible asset so that it is suitable for use or sale;
- the entity is able to demonstrate an intention to complete the asset and use or sell it;
- the intangible asset has the capacity to be used or sold;
- the entity can determine how the intangible asset will generate economic benefits;
- there are technical, financial and other resources available to complete the development and to use or sell the intangible asset;
- the expenditure related to the intangible asset is reliably measurable.

These expenditures are recognised in the consolidated statement of financial position under a separate heading 'Expenditure on development work (in progress)'.

Criteria for Assessing the Likelihood of Commercialisation of Projects

When the Group begins work on a particular project, it assesses whether the expenditure incurred should be classified as research or development. The following is first assessed: the scope of the work in question, what product it relates to, what are the regulatory requirements for that product, what is the potential market in which it is to be commercialised, and the Group's management assesses the likelihood of obtaining registration and the possibility of commercialisation according to the decision criteria below.

The Group makes a clear distinction between projects in terms of their likelihood of commercialisation. Consequently, it is possible to determine how the costs arising from them will be accounted for. The costs of projects whose commercialisation is uncertain will be charged to the current period's costs, while those whose commercialisation is certain are capitalised in accordance with the terms of IAS 38. The Group has set an internal probability level, the achievement of which will indicate that a given project and its expenditures may be subject to capitalisation - this level was set at no less than 70% probability.

The decision criteria for assessing probability relate to the following:

- the size and trend of the market affected by the project,
- compatibility of the new project with the Group's current portfolio,
- compatibility of the new project with the Group's commercial model,
- meeting the registration requirements in the shortest possible time,
- possessed production and laboratory facilities,
- sufficiency of financial resources or potential sources of financing through existing or future contracts,
- obtaining an independent or internal opinion on the implementation of the project.

Projects are evaluated annually according to the same business criteria as well as the requirements according to par 57 of IAS 38.

Impairment of non-financial assets

An asset is impaired when the carrying amount of an asset or a cash-generating unit exceeds its recoverable amount, being understood as the fair value reduced by the higher of the cost to sell and its use value. The calculation of fair value is based on a discounted cash flow model and is therefore sensitive primarily to future cash inflows and outflows.

Grants

The Group estimates the probability that the received subsidies will have to be returned. Depending on the adopted estimation, subsidies received may be recognized as profit or loss in the year in which costs financed by subsidies are incurred or suspended on deferred income until reasonable assurance of non-refundability of the amounts received is obtained.

The Group distinguishes three types of risks related to the reimbursement of grants received:

Risks relating to project implementation (risk number 1), in the opinion of the Parent Company's management, are as follows:

- the Group refuses to undergo or hinders the audit or does not implement the audit recommendations within the indicated timeframe;
- in the course of inspection proceedings carried out by authorized institutions, errors or shortcomings were found in the submitted documentation of the Project's environmental impact and these were not corrected or supplemented in due time;
- the Group fails to submit the payment application or interim report on time;
- the Group fails to correct the payment application or interim report containing deficiencies or errors within the set deadline;
- the Group fails to provide information and explanations about the implementation of the Project;
- the Group uses the grant money contrary to its purpose, collects the grant money unduly or in an excessive amount;
- the Group shall use the subsidy in breach of the procedures referred to in Article 184 of the Public Finance Act;
- the Interim Report was negatively evaluated by the authorized institutions as mentioned in the subsidy agreement;
- further implementation of the Project by the Group is impossible or pointless;
- the Group ceases to implement the Project or implements it in a manner contrary to the Agreement or in violation of law;
- there is a lack of progress in the implementation of the Project in relation to the deadlines specified in the application for co-financing, which results in a reasonable assumption that the Project will not be implemented in full or its objective will not be achieved.

The above risks are under the Group's control. The Group ensures that projects are implemented in compliance with the guidelines and provisions of the grant agreements. Project expenditures are incurred in compliance with the competitiveness principle, which is verified on three levels of project audit i.e. internal audit, verification of project expenditures when submitting a payment application in the SL System by the National Centre for Research and Development and verification of project expenditures conducted by an external company indicated by the National Centre for Research and Development.

Risks concerning the Group's operations (risk number 2), in the opinion of the Parent Company's management, are as follows:

- the Group or the Parent Company will make legal and organizational changes that threaten the implementation of the Agreement or will not inform the Intermediate Body about the intention to make legal and organizational changes that may have a negative impact on the implementation of the Project or the achievement of the Project objectives. This risk is controlled by the Group. The Parent Company's Management Board shall inform the Intermediate Body about all legal and organizational changes.
- the Group does not promote the Project as stipulated in the Agreement. This risk is controlled by the Group. The Group promotes the Projects at thematic scientific conferences and the execution of promotional activities is consistent with the Grant Agreements.
- laboratory facilities - The Group has existing laboratory facilities,
- inadequate resources of specialized personnel and laboratories capable of developing and implementing research to exploit new drug development technology,
- insufficient funds or potential sources of funding through existing or future licensing or collaboration agreements.

The risks relating to the Group's operations (risk number 2), in the opinion of the Parent Company's management, are presented below.

The Parent Company's Management Board ensures that the project sustainability requirement is met. In accordance with the Regulation (EU) No 1303/2013 of the European Parliament and of the Council of 17 December 2013 laying down common provisions on the European Regional Development Fund, the European Social Fund, the Cohesion Fund, the European Agricultural Fund for Rural Development and the European Maritime and Fisheries Fund and laying down general provisions on the European Regional Development Fund, the European Cohesion Fund and the European Maritime and Fisheries Fund and repealing Council Regulation (EC) No 1083/2006, and with funding agreements, the Group is required to ensure the durability of the project for a period of three years from their completion.

The principle of durability is breached in a situation where at least one of the prerequisites occurs during its duration:

- the Group ceases its activities or relocates them outside the programme support area,
- a change of ownership of an element of co-financed infrastructure occurs, which gives the company undue benefits,
- a significant change occurs that affects the nature of the project, its objectives or conditions of its implementation, which could result in a breach of its original assumptions.

Notwithstanding the above, it should be noted that the grant agreements with NCRD concern the implementation and financing of the Company's projects until the end of 2023. The Company estimates that some of its projects will enter Phase I of clinical trials in 2023, and some between 2023 and 2025. Even if the timetable estimated by the Company for some of the projects currently provides for entering Phase I of clinical trials in 2023, it cannot be excluded that such timetable will change and the projects will enter Phase I of clinical trials after 2023. As a result, the Company may not be able to use all of the funding received for a given project from the NCRD and will have to finance further work from its own funds. The Company is also exposed to the risk of the grant being withheld, significantly reduced or having to return some or all of the funds received from the grant.

Moreover, the Company received part of the NCRD funding as a member of a consortium. This situation occurred in the case of two projects: (i) the project "Development of laboratory kits for screening testing of chemical compounds in the development of a new class of drugs", under which the Company cooperated with the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences based in Wrocław, (ii) the project "Development and implementation of an innovative platform for screening analysis of degron-type therapeutic compounds" under which the Company cooperated with PORT Polski Ośrodek Rozwoju Technologii sp. z o.o. based in Wrocław (formerly Wrocławskie Centrum Badań EIT+ spółka z o.o.). In both cases, the Company and the other member of the consortium share the rights to the results of work and research under the project. As a result, the economic implementation of research results, e.g. their sale or licensing, requires the cooperation of the consortium members and cannot be carried out by the Company alone. Because of the necessity of cooperation of consortium members, the Company cannot exclude the risk of lack of cooperation from the other consortium member or inability to reach agreement on the terms of sale or implementation of project results, which might have adverse effects on the Company's operations, financial position, development prospects and results.

It should be additionally noted that agreements providing for sale or licensing of project results must meet a number of requirements that are more broadly described in the grant agreement. It cannot be precluded that some or all of the above-mentioned requirements will not be met, or that the Company will not be able to implement the results of research and

development work within the deadlines stipulated in the agreements, which may result in withholding the grant or terminating the grant agreement and being obliged to return all or part of the grant with interest.

Taxes

The interpretation of tax legislation, changes in tax law and the timing of taxable income are subject to uncertainty. Given the nature and complexity of existing contracts, they may lead to adjustments to recognised liabilities and assets and income tax provisions in the future.

14.2 Estimation uncertainty

The key assumptions about the future and other key sources of uncertainty at the balance sheet date that involve a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities in the next financial year are discussed below.

Impairment of non-financial assets

The Group assesses at each balance sheet date whether there is any indication that non-financial assets are impaired. If any indication exists that the carrying amount of these assets may not be recoverable, the Group tests the non-financial assets for impairment. As of the balance sheet date, in the opinion of the Group's Management Board, there is no indication of impairment of the carrying amount of non-financial assets held.

Valuation of provisions

Provisions for employee benefits (retirement and disability benefits) are determined on the basis of estimates (internal and external) and are updated at the end of each financial year. Estimates are made on the basis of formulas derived from past experience. As they are estimates, albeit the best in the opinion of management, there may be uncertainty associated with them.

The valuation of provisions for employee benefits is based on valuations prepared by independent external actuaries and is approved by the Parent Company's Management Board.

Provisions are recognised when the Group has an existing obligation (legal or constructive) as a result of a past event and when it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

Deferred tax asset

The Group recognises a deferred tax asset based on the assumption that future taxable profits will be available against which the asset can be utilised. Deterioration of the achieved tax results in the future could cause this assumption to become unjustified. The Parent Company's Management Board estimates the probability of realisation of tax profits, which has an impact on the recognition of deferred tax assets.

Depreciation rates

Depreciation rates are determined on the basis of the expected economic useful life of tangible and intangible assets. The Group reviews annually the adopted economic useful lives based on current estimates.

15. Important accounting principles

15.1 Consolidation principles

Principles for the consolidation of subsidiaries that meet the definition of a business

Subsidiaries controlled by the parent company in the Group that meet the definition of a business under IFRS 3 have been consolidated using the full method. Control is the power to govern the financial and operating policies of an enterprise so as to obtain economic benefits.

Subsidiaries are consolidated from the date that the Group obtains control over them and cease to be consolidated from the date that control ceases.

It is assumed that the Group exercises control if, and only if, the entity simultaneously:

- has power over the investee,
- by virtue of its involvement in the investee, is exposed to variable financial performance or has rights to variable financial performance,
- has the ability to use its power over the investee to affect its financial performance.

Control also exists when the Group has the power to govern the financial and operating policies of an entity.

In preparing consolidated financial statements, the Parent Company combines the financial statements of the Parent Company

and its Subsidiaries by aggregating the individual items of assets, liabilities and equity, income and expenses. The presentation in the consolidated financial statements should be ensured as if the Group were a single entity. For this purpose, the following shall be performed:

- exclusion of the carrying amount of the Parent Company's investment in each Subsidiary and that part of the equity of the subsidiaries corresponding to the Parent Company's interest,
- non-controlling interests in the net profit or loss of consolidated Subsidiaries for the reporting period are determined
- the identification and presentation separately from the Parent Company's equity of the non-controlling interests in the net assets of consolidated Subsidiaries.

Intercompany balances, transactions, dividends, income and expenses are eliminated in full. Profits and losses from intragroup transactions are recognised in assets - fixed assets, inventories - are eliminated in full.

Where losses indicate impairment, appropriate write-downs are made.

15.2 Tangible fixed assets

Fixed assets

Fixed assets are stated at acquisition cost (plus all costs directly attributable to the acquisition and preparation of the asset for use) or production cost, less accumulated depreciation and impairment losses. Fixed assets are depreciated on a straight-line basis starting from the month in which they are available for use. Depreciation rates are based on the economic useful lives of the assets. Fixed assets, except for land, are depreciated on a straight-line basis over their estimated useful economic lives.

Investments in third-party facilities are valued at cost, less depreciation. The length of depreciation corresponds to the lease term of such a third-party facility or its useful life, if shorter.

Each time an upgrade is completed, the cost is recognised in the carrying amount of property, plant and equipment if the recognition criteria are met. Costs incurred after the date an item of property, plant and equipment is placed in service, such as maintenance and repair costs, are charged to the income statement as incurred.

An item of property, plant and equipment may be derecognised from the statement of financial position upon disposal, termination of a contract in the case of leased assets, or when no future economic benefits are expected from its further use or sale. Any gain or loss arising on the removal of an asset from the statement of financial position, calculated as the difference between the sales proceeds and the carrying amount of the asset being removed, is recognised in profit or loss in the period in which the economic operation takes place.

The depreciation period for own fixed assets in accordance with the economic useful life is as follows:

- buildings and structures - the depreciation period is between 10 and 40 years,
- plant and machinery (mainly computer sets) - depreciation period is 3 to 25 years,
- means of transport - the depreciation period is 2.5 to 5 years,
- other fixed assets (including furniture, fixtures, office equipment) - depreciation period is between 13 months and 4 years.

The Group also leases laboratory equipment and office and laboratory space under long-term contracts, which under IFRS16 are treated as finance leases and shown on the Group's balance sheet. These assets are depreciated according to the duration of the contracts.

The Group conducted a fixed asset inventory in the fourth quarter of 2021.

Investments

Construction in progress relates to fixed assets under construction or assembly and is stated at acquisition or production cost, less any impairment losses. Fixed assets under construction are not depreciated until construction is completed and the asset is available for use.

The Group classifies a non-current asset (or group) as held for sale if its carrying amount will be recovered principally through a sale transaction rather than through continuing use.

The Group measures a non-current asset (or group) classified as held for sale at the lower of its carrying amount and fair value less costs to sell.

Subsequent expenditure

Subsequent costs incurred for the replaced parts of an item of property, plant and equipment that can be reliably estimated and

it is probable that the economic benefits associated with the replaced items of property, plant and equipment will flow to the Group are capitalised. Other expenditure is recognised as an expense on an ongoing basis in the result.

15.3 Intangible assets

Intangible assets are measured at purchase or production cost (if they meet the recognition criteria for research work), less any amortisation or depreciation and any impairment losses.

The cost of intangible assets acquired in a business combination is equal to their fair value at the date of the combination.

Each time the Group assesses whether an intangible asset has a limited or unlimited useful life.

Intangible assets with limited useful lives are amortised over their useful lives and tested for impairment whenever there are indications of impairment. The amortisation period and amortisation method for intangible assets with finite useful lives are reviewed at least at the end of each financial year. Changes in the expected useful life or the expected pattern of consumption of the economic benefits embodied in the asset are recognised by changing the amortisation period or method, as appropriate, and treated as changes in accounting estimates. The amortisation charge for intangible assets with finite useful lives is recognised in the income statement in the category that corresponds to the function of the intangible asset.

Intangible assets with indefinite useful lives and those that are not in use are reviewed for impairment annually, either on an asset-by-asset basis or at the cash-generating unit level.

The amortisation period for intangible assets is as follows:

- acquired property rights, licences and concessions - 2 years,
- other intangible assets - 2 years,
- development costs are amortised on a straight-line basis over the expected period of their economic usefulness.

Where it is not possible to separate an internally generated asset, development costs are recognised in profit or loss in the period in which they are incurred.

Research costs are not capitalised and are presented in the result as expenses in the period in which they are incurred.

The result arising from the removal of intangible assets from the statement of financial position is measured at the difference between the net disposal proceeds and the carrying amount of the asset and is recognised in the result when the asset is removed from the statement of financial position.

Research and development costs

Research costs are charged to the result as incurred. Expenditure incurred on development work performed as part of a project is carried forward if it can be deemed to be recoverable in the future. Subsequent to the initial recognition of development expenditure, the historical cost model is applied requiring assets to be carried at cost less accumulated depreciation and accumulated impairment losses. Any expenditure carried forward is amortised over the expected period of benefit to be derived from the project.

Development costs are reviewed for impairment annually - if the asset has not yet been placed in service, or more frequently - if during the reporting period an indication of impairment becomes apparent that its carrying amount may not be recoverable.

In order to correctly identify development work, the Group distinguishes it from research work. According to IAS 38, research work is an innovative and planned search for solutions undertaken with the intention of acquiring and assimilating new scientific and technical knowledge. Examples of research work according to IAS 38 include:

- activities aimed at acquiring new knowledge,
- the search for, evaluation and selection of the use of the results of research work or other knowledge,
- the search for alternative materials, devices, products, systems processes or services,
- the formulation, design, evaluation and final selection of new or improved materials, devices, products, processes, systems or services.

When generating intangible assets on its own, the Group allocates the expenditure to research and development accordingly. If the Group is unable to separate the research stage from the development stage, it treats the entire costs incurred as research stage costs. This results in charging the result for the period in which the costs were incurred. Expenditure incurred in the course of development work is recognised as an expense when incurred or is recognised as an intangible asset, depending on whether the criteria for capitalisation are met.

- It is possible to recognise expenditure and classify it as development work provided that:
- it is technically possible to complete the intangible asset so that it is suitable for use or can be held for sale,
- there is a realistic possibility that the intangible asset will generate probable future economic benefits,
- there is the ability to use or sell the intangible asset,
- there are available technical, financial and other resources and expenditures can be measured reliably,
- there is a method of implementation and applicability taking into account the existence of a market for the product.

When development expenditure meets the above conditions, the expenditure incurred is capitalised and reported in the statement of financial position as "Development expenditure (work in progress)".

In accordance with IAS 38, development cost includes all expenditure that is directly attributable to the activities of creating, producing and adapting an asset for use in the manner intended by management. These expenditures include:

- expenditures for materials and services used or consumed in generating the intangible asset,
- costs of employee benefits arising directly from the generation of the intangible asset,
- fees to register a legal title,
- amortisation of patents and licences that are used to generate the intangible asset.

Development work in progress (ongoing)

The commencement of development work is documented by the opening of a project charter. Based on this documentation, the moment from which expenditures in a given project are treated as development work in progress and are capitalised in the assets of the statement of financial position, under intangible assets, analytically under "development work in progress", is determined. This item is not amortised but is subject to impairment testing.

Development work completed

A development project is subject to closure if the following criteria are met:

- the scope of work under the project charter and grant agreement has been completed,
- the work is abandoned, in which case the expenditure is charged to other operating costs.

At the end of each reporting period, the Parent Company's Management Board assesses whether there are any indications that assets from development work in progress may be impaired. If such indications are found, an appropriate test is performed. If the carrying amount of the assets tested exceeds their recoverable amount, an appropriate impairment loss is recognised.

When assessing the existence of indications of possible impairment of intangible assets, the Group analyses indications coming from external and internal sources of information required by IAS 36 "Impairment of assets".

In the opinion of the Parent Company's Management Board, development work is capitalised once the capitalisation criteria set out in § 57 of IAS 38 "Intangible Assets" are met.

15.4 Leasing

Under IFRS 16, the Group classifies arrangements as leases if, under the arrangement, the Group obtains the right to control the use of an identified asset for a specified period in return for consideration. The entity reassesses whether an arrangement is or contains a lease only if the terms of the arrangement change.

For an arrangement that is a lease, the Group applies a practical expedient and does not separate the non-lease elements from the lease elements and instead recognises each lease element and any accompanying non-lease elements as a single lease element.

The Group applies a single recognition and measurement approach for all leases to which it is a lessee, except for short-term leases and leases of low-value assets, which are recognised as an expense in earnings on a straight-line basis over the lease term.

In determining the lease term for leases with an indefinite term, the Group exercises professional judgement taking into account:

- the expenditures incurred in relation to a particular contract; or
- the potential costs of terminating the lease, including the costs of obtaining a new lease, such as negotiation costs, relocation costs, the costs of identifying another underlying asset to meet the lessee's needs, the costs of integrating the new asset into the lessee's operations, or termination penalties and similar costs, including the costs of returning the underlying asset in the condition specified in the contract or to the location specified in the contract.

Where the costs associated with termination of the lease are significant, the lease term is assumed to be the same as the assumed depreciation period for a similar fixed asset with characteristics similar to those of the leased asset. To the extent that the costs associated with termination of the lease are reliably determinable, the lease term over which termination is not justified is determined. When the expenditure incurred on a particular arrangement is significant, the lease term is the period over which the economic benefits from the use of the expenditure are expected to flow. The value of the expenditure incurred is a separate asset from the right-of-use asset. If there is no expenditure on a contract, or no termination costs, or if the expenditure is immaterial, the termination period is the lease term.

The Group recognises right-of-use assets at the commencement date of the lease (i.e. the date that the underlying asset is available for use). Right-of-use assets are measured at cost, less accumulated depreciation and impairment losses, adjusted for any revaluation of lease liabilities. The cost of right-of-use assets comprises the amount of recognised lease commitments, initial direct costs incurred and any lease payments made on or before the commencement date, less any lease incentives received. Unless the Group is reasonably certain that it will obtain ownership of the leased asset at the end of the lease term, recognised right-of-use assets are amortised on a straight-line basis over the shorter of the estimated useful life or the lease term.

At the inception of the lease, the Group measures its lease liabilities at the present value of the lease payments outstanding at that date. Lease payments comprise fixed payments (including substantially fixed lease payments) less any lease incentive payable, variable payments that depend on an index or rate and amounts expected to be paid under the guaranteed residual value. Lease payments also include the exercise price of a call option, if the exercise by the Group can be assumed with reasonable certainty, and payments of lease termination penalties, if the terms of the lease provide for the Group's ability to terminate the lease. Variable lease payments that do not depend on an index or rate are recognised as an expense in the period in which the event or condition giving rise to the payment occurs.

In calculating the present value of lease payments, the Group uses the lessee's incremental borrowing rate at the inception of the lease if the lease rate cannot be readily determined. After the commencement date, the amount of the lease liability is increased to reflect interest and reduced by lease payments made. In addition, the carrying amount of the lease liability is remeasured if there is a change in the lease term, a change in the substantially fixed lease payments, or a change in judgement regarding the purchase of the underlying assets.

Leases where control of the assets does not pass are operating leases. Lease payments made under operating leases (adjusted for any special promotional offers received from the lessor (financing party) are charged to expense on a straight-line basis over the lease term.

15.5 Impairment of non-financial fixed assets

At each balance sheet date, the Group assesses whether there is any indication that a non-financial non-current asset may be impaired. If any such indication exists, or if an annual impairment test is required, the Group estimates the recoverable amount of the asset or the cash-generating unit to which the asset belongs.

The recoverable amount of an asset or a cash-generating unit is the higher of the asset's or cash-generating unit's fair value less costs to sell and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. If the carrying amount of an asset is greater than its recoverable amount, an impairment loss occurs and a write-down to the determined recoverable amount is made. In assessing value in use, the projected cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Impairment losses on assets used in continuing operations are recognised in those expense categories that correspond to the function of the asset that is impaired.

At each balance sheet date, the Group assesses whether there is any indication that an impairment loss recognised in prior periods in respect of an asset is no longer necessary or should be reduced. If such indications exist, the Group estimates the recoverable amount of the asset. A previously recognised impairment loss is reversed if, and only if, there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. If this is the case, the carrying amount of the asset shall be increased to its recoverable amount. The increased amount cannot exceed the carrying amount of the asset that would have been determined (net of depreciation or amortisation) had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss for an asset is recognised as income in the income statement. After the reversal of an impairment loss is recognised, the depreciation charge for the asset is adjusted in future periods to allocate the asset's revised carrying amount, less its residual value, on a systematic basis over its remaining useful life.

15.6 Borrowing costs

Under the permitted alternative treatment of IAS 23, borrowing costs that are directly attributable to the acquisition, construction or production of an asset are included in the cost of that asset. Such borrowing costs are capitalised as part of the cost of an asset if it is probable that they will result in future economic benefits to the entity and the cost can be measured reliably. Other borrowing costs are recognised as an expense in the period in which they are incurred. Borrowing costs comprise interest and foreign exchange gains or losses to the extent of any adjustment to interest expense. The Group has not to date used external sources to finance the cost of assets.

15.7 Financial assets

At the date of acquisition, the Group measures financial assets at fair value, which is usually the fair value of the consideration paid. The Group includes transaction costs in the initial measurement of all financial assets, except for the category of assets measured at fair value through profit or loss. An exception to this principle is trade receivables, which the Group measures at their transaction price as defined in IFRS 15, except for those trade receivable items with a maturity of more than one year that contain a significant financing component as defined in IFRS 15.

For the purpose of measurement after initial recognition, financial assets other than hedging derivatives are classified by the Group into:

- financial assets measured at amortised cost,
- financial assets at fair value through other comprehensive income,
- financial assets at fair value through profit or loss, and
- equity instruments at fair value through other comprehensive income.

These categories determine the measurement principles at the balance sheet date and the recognition of measurement gains or losses in profit or loss or other comprehensive income. The Group classifies financial assets into categories based on the Group's business model for managing financial assets and the contractual cash flows specific to the financial asset. A financial asset is measured at amortised cost if both of the following conditions are met (and not designated on initial recognition as at fair value through profit or loss):

- the financial asset is held in accordance with a business model whose objective is to hold the financial asset to collect the contractual cash flows,
- the contractual terms of the financial asset give rise, on specified dates, to cash flows that are solely payments of principal and interest on the principal amount outstanding.

The Group includes in the category of financial assets measured at amortised cost:

- loans,
- bonds
- trade and other receivables (excluding those for which IFRS 9 does not apply),
- debt securities.

These classes of financial assets are presented in the statement of financial position with a breakdown into long-term and short-term assets under the headings "Loans granted", "Trade and other receivables" and "Other financial assets". The valuation of short-term receivables is carried out at the value to be paid due to insignificant discounting effects. Interest income determined using the effective interest rate method is recognised by the Group in the result under a separate item. Losses on impairment of financial assets measured at amortised cost less gains on reversal of impairment losses, as well as gains and losses arising from exclusion of assets belonging to this category from the statement of financial position, are recognised by the Group in the result under separate items. Other gains and losses on financial assets recognised in the result, including exchange rate differences, are presented as financial income or expenses.

Financial assets included in the categories measured at amortised cost and measured at fair value through other comprehensive income due to their business model and the nature of the flows associated with them are assessed at each balance sheet date to recognise expected credit losses, regardless of whether there is any indication of impairment.

The method of making this assessment and estimating the allowance for expected credit losses differs for different classes of financial assets:

- for trade receivables, the Group applies a simplified approach that assumes the calculation of allowances for expected credit losses for the entire life of the instrument. Allowance estimates are made on a pooled basis and receivables have been

grouped by overdue period. The estimate of the allowance is based primarily on historical past due amounts and a link between past due amounts and actual repayments over the past 5 years, taking into account available forward looking information,

- for other asset classes, in the case of instruments for which the increase in credit risk since initial recognition has not been significant or the risk is low, the Group assumes first recognition of default losses for the next 12 months. If the increase in credit risk since initial recognition has been significant, losses are recognised as appropriate over the life of the instrument.

The Group has assumed that a significant increase in risk occurs when overdue payments exceed 365 days.

15.8 Impairment of financial assets

At each balance sheet date, the Group assesses whether there is objective evidence that a financial asset or a group of financial assets is impaired.

Assets carried at amortised cost

If there is objective evidence that an impairment loss on loans and receivables measured at amortised cost has been incurred, the amount of the impairment loss is equal to the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future expected credit losses not yet incurred) discounted at the financial asset's original effective interest rate (i.e. the effective interest rate computed at initial recognition). The carrying amount of the asset is reduced either directly or through a write-down. The amount of the loss is recognised in profit or loss.

The Group first assesses whether objective evidence of impairment exists individually for financial assets that are individually significant, as well as evidence of impairment for financial assets that are not individually significant. If the analysis shows that there is no objective evidence of impairment for an individually assessed financial asset, whether significant or not, the Group includes the asset in a group of financial assets with similar credit risk characteristics and collectively assesses it for impairment. Assets that are individually assessed for impairment and for which an impairment loss has been recognised or an existing impairment loss is deemed to remain unchanged are not considered in the collective assessment of a group of assets for impairment.

If, in a subsequent period, the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed. A subsequent reversal of an impairment loss is recognised in profit or loss to the extent that the carrying amount of the asset does not exceed its amortised cost at the date of reversal.

15.9 Trade and other receivables

Trade receivables are recognised and reported at fair value, i.e. at the amounts originally invoiced. Subsequent to initial recognition, short-term receivables are measured at the amount payable due to the fact that they are repaid on an ongoing monthly basis and their measurement at adjusted cost is broadly consistent with such measurement.

At each balance sheet date, the Group's management assesses the probability of recovering the receivables. The value of receivables is updated taking into account the degree of probability of their payment. An allowance for receivables is estimated when collection of the full amount of the receivable is no longer probable. The Group assumed that a significant increase in risk occurs when overdue payments exceed 365 days. In addition to the above criteria, an individual approach is applied to selected receivables.

15.10 Cash and cash equivalents

Cash comprises cash at banks and in hand, deposits held at call with banks, other short-term investments with original maturities of three months or less and highly liquid investments.

Cash is valued at nominal value, except that the value of bank deposits also includes capitalised interest credited to the bank account.

The balance of cash and cash equivalents shown in the consolidated statement of cash flows consists of cash and cash equivalents as defined above.

15.11 Interest-bearing bank loans, borrowings and debt securities

At initial recognition, all bank loans, borrowings and debt securities are recognised at the fair value of the cash received, net of any costs associated with obtaining the loan.

After initial recognition, interest-bearing loans, borrowings and debt securities are measured at amortised cost using the effective interest method. Determination of the amortised cost shall take account of costs related to obtaining the credit or loan and discounts or premiums received in connection with the liability.

Income and expenses that are not directly attributable to the acquisition, construction or production of a qualifying asset are recognised in profit or loss in the period in which they are incurred or earned.

15.12 Trade and other payables

Trade and other payables representing financial liabilities are measured at fair value. After initial recognition, these liabilities are measured at amortised cost or at the amount required to be paid, provided there are insignificant discounting effects.

Other non-financial liabilities include, in particular, liabilities for value added tax and liabilities for advance payments received that will be settled by the delivery of goods, services or fixed assets. Other non-financial liabilities are recognised at the amount payable.

Other financial liabilities, are measured at amortised cost using the effective interest rate method.

The Group removes a financial liability from the statement of financial position when the obligation is extinguished - that is, when the obligation specified in the contract is discharged, cancelled or expires. When an existing debt instrument is replaced by an instrument with substantially different terms and conditions between the same parties, the Group recognises the expiry of the original financial liability and the recognition of a new financial liability. Similarly, significant modifications to the terms of an agreement relating to an existing financial liability are recognised by the Group as extinguishment of the original financial liability and recognition of a new financial liability. The resulting differences in carrying amounts are recognised in profit or loss.

15.13 Provisions

Provisions are created when the Group has a present legal or constructive obligation as a result of a past event and it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made of its value. Where the Group expects that the costs covered by a provision will be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset, but only when it is virtually certain that the reimbursement will actually occur. The costs relating to a provision are shown in the result net of any reimbursement.

15.14 Retirement and jubilee bonuses

The Group companies do not have jubilee award rights in their bylaws. The Group estimates the amount of provisions for retirement severance pay, disability benefits, post-death benefits and unused annual leave at each balance sheet date. Provisions are charged to the consolidated profit or loss. The calculation of employee provisions is performed by external, independent actuaries.

15.15 Distribution of profit to staff and special funds

The Company does not allocate profits to employees or to special funds. The generated profit may be retained in the Company or allocated for payment of dividends.

15.16 Grants

The Group operates in the biopharmaceutical industry, specialising in the development of drugs that induce targeted degradation of pathogenic proteins. The Group benefits from government grants, mainly from the National Centre for Research and Development (NCRD). The Group receives grants in the form of cash upon fulfilment of the conditions set out in the grant agreements and upon acceptance of payment applications. This is done after the Group has incurred expenses, either in the form of reimbursement (refund) or in the form of advance payments.

Government grants, including non-monetary grants recognised at fair value, are recognised only when there is reasonable assurance that the Group will satisfy the conditions attached to the grant and that the grant will actually be received. Where a grant relates to a specific cost item, it is recognised as income over the period necessary to match it with the related costs which the grant is intended to compensate. On the other hand, if a grant relates to a specific asset, then its fair value is recognised in the deferred income account and then it is gradually recognised in the income statement as revenue in proportion to the depreciation write-offs made on that asset.

Grants may relate to expenditure on research and development work (intangibles) or fixed assets.

When a grant becomes repayable, it results in a change of estimate and the repayment of the grant is recognised immediately in profit or loss.

The risks of grant reimbursement are further described in point 14 *Significant values based on professional judgement and*

estimates in the paragraph "Grants".

The Criteria for Assessing the Likelihood of Commercialisation of Projects are further described in point 14 *Significant values based on professional judgement and estimates* in the paragraph "Criteria for Assessing the Likelihood of Commercialisation of Projects".

Revenues from subsidies are presented in item “Subsidies”.

Subsidies received by the Group are presented in the table below.

Project name	Project number	Project budget	Grant from the NCRD	Grant program name	Amount received until 31.12.2022-. to the Group's bank account (PLN)
Development of new anti-inflammatory drugs degrading cell surface receptors*	CT-06 POIR.01.01.01-00-0747/16	31,989,076.35	24,460,807.48	Smart Development Program 2014-2020	12,026,641.60
Development of laboratory kits for screening testing of chemical compounds in the development of a new class of drugs	PT-02 POIR.04.01.02-00-0147/16***	2,165,085.00	1,685,268.00	Smart Development Program 2014-2020	1,620,096.18
Development and implementation of an innovative platform for screening analysis of degron-type therapeutic compounds	PT-01 POIR.04.01.04-00-0116/16***	2,950,155.00	2,241,369.00	Smart Development Program 2014-2020	1,751,795.85
Apoptosis induction using low molecular weight chemical compounds as a therapeutic intervention in neoplastic diseases	CT-03 POIR.01.01.01-00-0956/17	35,902,013.75	27,683,098.00	Smart Development Program 2014-2020	16,884,392.66
Application of the targeted protein degradation technology in the treatment of psoriasis and rheumatoid arthritis	CT-05 POIR.01.02.00-00-0079/18	37,130,943.75	29,558,070.00	Smart Development Program 2014-2020	14,036,247.82
Preparation and development of a first-in-class drug candidate, small molecule degrader, in the treatment of colon cancer	CT-04 POIR.01.02.00-00-0073/18	32,041,906.25	25,510,680.00	Smart Development Program 2014-2020	11,759,622.31
Preparation and development of a drug candidate in the treatment of hepatocellular carcinoma, enabling elimination of cancer stem cells, through induced degradation of carcinogen induced transcription factor.	CT-01 POIR.01.01.01-00-0740/19	36,389,016.25	28,959,643.00	Smart Development Program 2014-2020	11,999,697.59
Preparation and development of non-toxic ligase ligands and their application in autoimmune diseases	CT-02 POIR.01.01.01-00-0741/19	34,411,900.00	27,411,400.00	Smart Development Program 2014-2020	5,120,367.48
Development of an integrated technological platform in the area of targeted protein degradation and its implementation on the pharmaceutical market	PT-03 POIR.01.01.01-00-0931/19	10,135,628.75	7,759,469.50	Smart Development Program 2014-2020	4,967,763.38
Total		223,145,725.10	175,129,010.30		80,166,624.87

*The Parent Company does not intend to continue the indicated project;
** In case of realization of the project in a consortium, the indicated amount includes only co-financing foreseen for the Parent Company;
*** The Company is not continuing the indicated project with NCBiR.

15.17 Revenues

Sales revenues

In accordance with IFRS 15, revenue is recognised when the goods or services are transferred to the customer (the customer) in an amount that reflects the consideration the entity expects to receive in exchange for the goods or services, i.e. when the performance obligations are met.

The Group recognises a contract with a customer only when all of the following criteria are met:

- parties to a contract have entered into a contract and are obliged to perform their obligations,
- the performance obligations can be identified,
- the transaction price can be determined, i.e. the entity is able to identify the terms of payment for the goods or services to be transferred,
- the contract has economic substance, i.e. the risk, timing or amount of the entity's future cash flows can be expected to change as a result of the contract,
- it is probable that the entity will receive the consideration to which it is entitled in exchange for the goods or services to be transferred to the customer. The assessment of whether it is probable that the consideration will be received considers only the customer's ability and intention to pay the consideration in a timely manner.

The Group recognises revenue when the performance obligation is fulfilled by transferring the promised goods or services to the customer. The transfer of the asset occurs when the customer obtains control of the asset.

The Group transfers control of the good or service over time, thereby satisfying the performance obligation, and recognises revenue over time when one of the following conditions is met:

- the customer simultaneously receives and benefits from the Entity's performance as the entity performs the obligation,
- as a result of the Entity's performance of the obligation, an asset is created or improved and control of the asset, as it is created or improved, is vested in the customer.

15.18 Taxes

Current tax

Current tax liabilities and receivables for the current and prior periods are measured at the amount expected to be paid to the tax authorities.

The tax shown in the result is the current tax charged on the result of the Group's reporting period and the deferred part, representing the change in the balance of deferred tax assets and liabilities in the period.

Deferred tax

For financial reporting purposes, deferred tax is calculated using the balance sheet liability method in respect of temporary differences at the balance sheet date between the carrying amounts of assets and liabilities shown in the consolidated financial statement and their tax bases. Deferred tax liabilities are recognised for all taxable temporary differences.

Deferred tax assets are recognised for all deductible temporary differences, as well as unused tax credits and unused tax losses carried forward to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, assets and losses can be utilised.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. An unrecognised deferred tax asset is reassessed at each balance sheet date and is recognised to the extent that it is probable that future taxable profits will be available against which the asset can be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the balance sheet date.

Income tax relating to items recognised outside profit or loss is recognised outside profit or loss in other comprehensive income relating to items recognised in other comprehensive income or directly in equity relating to items recognised directly in equity.

The Group offsets deferred tax assets against deferred tax liabilities if and only if it has a legally enforceable right to set off current tax assets against current tax liabilities and the deferred tax relates to the same taxable entity and the same taxation authority.

The possibility of accounting for tax losses is subject to the judgement of the Entity's management and is dependent on tax revenue forecasts and plans with respect to commercialisation of ongoing research and development projects. In accordance with the prudence principle, the Group has not recognised assets for tax losses.

Value added tax

Revenues, expenses, assets and liabilities are recognised net of value added tax, except:

- where the value added tax paid on the purchase of assets or services is not recoverable from the tax authorities, in which case it is recognised as part of the cost of the asset or as part of the expense item as appropriate; and
- receivables and payables, which are reported including the amount of value added tax.

The net amount of value added tax recoverable from, or payable to, the tax authorities is included in the consolidated statement of financial position as part of receivables or payables.

15.19 Net earnings per share

Net earnings per share for each period is calculated by dividing the Group's net profit and net profit attributable to equity holders of the Parent Company for the period by the number of shares at the end of the reporting period. Any issue of ordinary shares during the financial year gives entitlement to a dividend from the beginning of the financial year.

Diluted earnings per share are calculated by dividing net profit for the period attributable to ordinary shareholders of the Parent Company by the likely number of shares including future issues.

15.20 Equity

Equity is assets less liabilities and provisions for liabilities. Equity is recognised in the consolidated financial statement by type and in accordance with the principles laid down by law, the provisions of the Parent Company's Statute.

The Parent Company's share capital is the share capital of the Group and is stated at the nominal value of the registered shares, resulting from the Parent Company's statute and entry in the National Court Register. Share premium arises from share issues and is reduced by issue costs (including the effect of income tax) and is recognized in the share premium reserve. The share-based payment reserve includes the equivalent of costs of payments in the form of securities recognised in accordance with IFRS2. Retained earnings/uncovered losses represent accumulated profits/losses that have not been distributed by the General Meeting.

15.21 Employee share ownership programme – share-based payments

The Parent Company operates an equity-settled share-based benefit plan under which employees have the opportunity to acquire shares in the Parent Company upon satisfying the conditions set out in the Incentive Plan Regulations. The scheme covers a total of no more than 237,244 ordinary shares in the Parent Company.

The Incentive Scheme was established pursuant to Resolution No. 14 of the Parent Company's Annual General Meeting of 16 May 2019, as amended by Resolution No. 22 of the Parent Company's Annual General Meeting of 26 June 2020 and Resolution No. 10 of the Parent Company's Extraordinary General Meeting of 8 January 2021. On the basis of the Incentive Scheme, eligible persons (i.e. persons employed in the Parent Company or its subsidiaries, on the basis of an employment contract or other legal basis, indicated by the Management Board of the Parent Company after obtaining the approval of the Supervisory Board, as well as members of the Supervisory Board indicated by the General Meeting) will have the right to purchase existing or newly issued shares of the Parent Company. The decision as to whether the Parent Company will offer employees the treasury shares acquired by the Parent Company from the shareholders of the Parent Company (the Parent Company's primary obligation) or issue newly issued shares (the so-called alternate authorisation) has been left to the Parent Company.

The sale price per share (or issue price in the case of newly issued shares) is PLN 0.10 (ten groszy), i.e. employees participating in the Incentive Scheme will be able to purchase (take up) shares at the issue price corresponding to the nominal value of the shares. The number of shares in the Parent Company to be offered to a given employee shall depend on the decision of the Management Board and the Supervisory Board, which shall be guided by such criteria as the employee's position, length of service, assessment of the employee's contribution to the value of the Parent Company to date and the importance of the employee's position to the achievement of the objectives of the Parent Company. In order to participate in the Incentive Scheme, employees of the Parent Company will conclude agreements on participation in the Incentive Scheme, on the basis of which shares will be acquired in four equal tranches falling on the first, second, third and fourth anniversary of the conclusion of the agreement on participation in the Incentive Scheme. The condition for acquiring the right to successive tranches is that the employee remains employed on the dates of successive anniversaries of signing the agreement on participation in the Incentive Scheme. Employees of the Parent Company in agreements concerning participation in the Incentive Scheme undertake towards the Parent Company not to dispose of the acquired shares for a period of one year from the date of acquisition of a given tranche of shares (in accordance with the resolution of the Supervisory Board of 22 February 2021 amending the Rules of the Incentive Scheme, the Supervisory Board agreed that the above-mentioned obligation not to dispose of shares shall last for a period of one year from the date of fulfilment

of the condition entitling to acquire a given tranche. The above amendment was implemented by the Parent Company to the agreements concluded to date for participation in the Incentive Programme and will also be applied in agreements for participation concluded in the future).

The valuation of employee share schemes is based on IFRS2. The Parent Company has decided to estimate the fair value of the rights arising from the Incentive Scheme by an external, independent actuary. The fair value of the rights is recognised as an expense over the vesting period.

The total amount to be recognised as an expense is determined by reference to the fair value of the shares granted, determined at the grant date:

- taking into account any market conditions (for example, the Entity's share price),
- without taking into account the effect of any seniority-related or non-market vesting conditions (for example, sales profitability, sales growth targets and the indicated period of mandatory service with the Entity).

At the end of each reporting period, the Parent Company revises its estimates of the expected number of shares that will vest as a result of non-market vesting conditions. The Group presents the effect of any revision to the original estimates in the statement of profit or loss, with a corresponding adjustment to equity.

According to the valuation, the value of the incentive programme is as follows in each quarter for the years 2023-2026:

Quarter	Cumulative costs	Cost of the period
2023 Q1	21,103	1,318
2023 Q2	22,389	1,286
2023 Q3	23,273	884
2023 Q4	24,026	753
2024 Q1	24,667	641
2024 Q2	25,279	611
2024 Q3	25,620	342
2024 Q4	25,885	265
2025 Q1	26,071	186
2025 Q2	26,237	166
2025 Q3	26,301	64
2025 Q4	26,327	27
2026 Q1	26,335	7
2026 Q2	26,341	6
2026 Q3	26,345	4

The above values are subject to change in subsequent periods in the event of the granting of rights to new employees or the termination of cooperation with existing employees, which will entail the loss of their granted rights.

15.22 Other assets and liabilities

Prepayments and accrued income

The Group makes prepaid expenses when they relate to future reporting periods. Prepayments include prepayments for services or goods that have not been delivered or performed.

Deferred income

Deferred income represents grants received.

The current portion of deferred revenue represents that portion in respect of which the Parent Company's Management Board expects to be able to qualify as revenue (or to reduce expenses) within 12 months of the balance sheet date.

15.23 Information on business segments

A company is organised and managed by segments, taking into account the type of products and services offered. Each operating segment represents a strategic business unit offering different products and goods. Operating segments are aggregated into reportable segments based on the nature of the business.

Management believes that the Group has one reportable segment - research and development.

Due to the existence of one reportable segment, the Management Board of the Parent Company has refrained from preparing information on operating segments.

15.24 Financial income and costs

Financial income represents income related to the financing of operations. Specifically, financial income includes net foreign exchange gains arising solely on liabilities from sources of financing the entity's operations (loans, credits, bonds, financing leases, etc.), income from the realization and fair value measurement of derivatives related to liabilities financing the entity's operations (loans, credits, bonds, financing leases, etc.), gains from the valuation of a financial instrument that is a liability financing the entity's operations and is a hedged item.

Finance costs represent costs related to the external financing of operations. Specifically, financing costs include interest on bank overdrafts, interest on short-term and long-term borrowings, loans and other sources of financing, including discounting of liabilities, financing charges under lease agreements, recognized in accordance with IFRS16, net foreign exchange losses arising solely on liabilities from sources of financing the entity's operations, changes in the amount of provisions resulting from approximating the time of financing the liability (the so-called "reverse discounting effect"). effect of inverse discounting) in the case of provisions, the amount of which is determined by discounting the amount of estimated future cash flows necessary to be incurred to meet the obligation, as well as the increase in the value of other liabilities caused by inverse discounting.

SELECTED EXPLANATORY NOTES TO THE CONSOLIDATED FINANCIAL STATEMENT

16. Total revenues

	01.01.2022	01.01.2021
SALES REVENUES AND TOTAL REVENUES	-	-
	31.12.2022	31.12.2021
Revenue from research and development services	9,158	3,986
Total sales revenues	9,158	3,986
Subsidies	20,577	21,949
Other operating income	2,269	2,694
Financial income	3,127	-
Total revenues	35,131	28,629

In 2022, the Parent Company continued its collaboration with the Sosei Heptares firm, which aims to discover and develop new small molecules targeting the degradation of G protein-coupled receptors, and in November 2022, another collaboration agreement was concluded with the Ono Pharmaceutical firm, which may have a target primarily in the field of neurodegenerative diseases. As a result, the Group generated total revenues of PLN 9.2 million from these two agreements in 2022.

A detailed description of the reported amount of other operating income is presented in Note 18.

The Group recorded an increase in other operating income in 2022 compared to the previous year, as described in Note 19.

The structure of revenues from the received subsidies and settled phases of particular projects is presented below:

	31 December 2022	Structure % 2022	31 December 2021	Structure % 2021
CT-04 POIR.01.02.00-00-0073/18	947	5%	3,044	14%
CT-03 POIR.01.01.01-00-0956/17	1,874	9%	3,685	17%
CT-02 POIR.04.01.04-00-0116/16	-	-	-	-
PT3 POIR.01.01.01-00-0931/19	3,153	15%	2,085	10%
CT-06 POIR.01.01.01-00-0747/16	-	-	117	1%
CT-01 POIR.01.01.01-00-0740/19	4,854	24%	4,947	23%
CT-02 POIR.01.01.01-00-0741/19	3,794	18%	3,543	16%
CT-05 POIR.01.02.00-00-0079/18	5,955	29%	4,528	21%
Total	20,577	100%	21,949	100%

17. Costs by type

17.1 Operating expenses

	01.01.2022	01.01.2021
OPERATING EXPENSES	-	-
	31.12.2022	31.12.2021
Depreciation	7,094	7,355
-depreciation of fixed assets	6,856	7,226
-amortisation of intangible assets	238	129
Consumption of materials and energy	4,296	4,460
External services	31,343	17,054
Taxes and charges	357	224
Costs of employee benefits	26,704	25,211
Other costs by nature	516	230
Total costs by type, including:	70,310	54,534
Items recognised in costs of sales of services	2,087	741
Items included in research costs	44,155	23,115
Items included in project overheads	4,510	11,133
Items included in general administrative costs	19,558	19,545
Change in products	-	-
Costs of services for the entity's own needs	-	-

The increase in the Group's operating expenses compared to the comparative period is mainly due to an increase in the cost of third-party services and employee benefit costs related to base salaries and additional cash gratuities. In addition, the increase in employee benefit costs is also closely related to the costs of the incentive program. A breakdown of employee costs is indicated in Note 17.3.

In view of the achievement of further milestones and the acceleration of research processes during 2022, and in particular the change in the cost structure between the costs quantified from the funding received from NCBiR and the Group's own costs, in order to increase the transparency of the information provided to the recipients of the financial statements, the Group decided at the stage of preparing these consolidated financial statements to reclassify and change the presentation of the portion of general costs of the project reported during 2022 to research costs. In the previous year, research costs financed with own funds were treated as overall project overheads in their entirety. The Group classifies all direct costs incurred in connection with ongoing research projects (regardless of the source of financing) as research expenses, including in particular costs related to salaries of researchers, third-party services, and other direct costs such as materials and labor, electricity and other media, depreciation of research assets, etc. Unlike research work costs, project overheads include costs not allocated to individual research projects. The main titles of costs included as project overheads are, in particular, costs of personnel involved in project management, costs of personnel, financial, administrative and legal services, costs of maintaining office space related to project administrative services and other costs related to project administration and service. The above change has the value of a presentation change only, and does not affect the change in the total value of research and project overheads and the Group's financial result. Due to the above-mentioned change, the value of project overheads presented in the consolidated statement of earnings and other comprehensive income for the period from January 1 to December 31, 2022 is lower than the value of costs presented in the interim condensed consolidated financial statements for the period from January 1 to June 30, 2022 and for the three-month period ended September 30, 2022.

In the course of preparing this financial statement, the Parent Company's Management Board has taken all reasonable efforts and actions to determine the possible amount of costs included in the financial result of 2021 and presented as project overheads, which, given the above-described change in presentation in 2022, should be presented as research work baskets in the comparative data for 2021. Bearing in mind para. 42 of International Accounting Standard No. 1 "Presentation of financial statements", due to the significant labor intensity associated with the possible recalculation of comparative data in relation to the informative value resulting from the demonstration of a fully analogous breakdown of costs, it was decided not to restate comparative data, given that the change in 2022 was only of a presentational nature between research work costs and project overheads.

17.2 Depreciation and amortisation expenses included in the result

	01.01.2022	01.01.2021
DEPRECIATION AND AMORTIZATION EXPENSES INCLUDED IN THE RESULT	-	-
	31.12.2022	31.12.2021
Items included in cost of services sold	175	42
Depreciation of fixed assets	168	42
Amortisation of intangible assets	7	-
Impairment of property, plant and equipment	-	-
Impairment of intangible assets	-	-
Items included in research costs	6,030	5,807
Depreciation of fixed assets	5,820	5,690
Amortisation of intangible assets	209	117
Impairment of property, plant and equipment	-	-
Impairment of intangible assets	-	-
Items included in project overheads	726	1,488
Depreciation of fixed assets	726	1,478
Amortisation of intangible assets	-	10
Impairment of property, plant and equipment	-	-
Impairment of intangible assets	-	-
Items included in general and administrative costs	164	18
Depreciation of fixed assets	142	15
Amortisation of intangible assets	21	3
Impairment of property, plant and equipment	-	-
Impairment of intangible assets	-	-
Total of depreciation and impairment allowances	7,094	7,355

17.3 Employee benefit costs

	01.01.2022	01.01.2021
EMPLOYEE BENEFIT COSTS	-	-
	31.12.2022	31.12.2021
Wages and salaries	14,771	13,292
Social security costs	2,380	1,849
Pension and holiday benefit costs	139	152
Other employee benefit costs	1,408	423
Costs of incentive programme	8,006	9,495
Total employee benefit costs, including:	26,704	25,211
Items included in cost of sales of services	617	472
Items included in research costs	11,626	7,373
Items included in project overheads	639	2,645
Items included in general administrative costs	13,822	14,721
Change in products	-	-
Costs of services for the entity’s own needs	-	-

The main share in the costs of employee benefits is represented by the costs of salaries of the Group’s employees, which in 2022 amounted to PLN 14,771 thousand and the costs of the incentive programme introduced in 2019, the cost of which in 2022 amounted to PLN 8,006 thousand (whereas it is an accounting costs not related to the real outflow of cash). Details of this programme and its valuation in subsequent quarters are described in "Accounting principles (policy) and additional information".

18. Other operating income and expenses

	01.01.2022	01.01.2021
OTHER OPERATING INCOME	-	-
	31.12.2022	31.12.2021
Profit from disposal of fixed assets	-	-
Release of asset write-downs	-	1,131
Donation	2,000	1,000
Other	269	563
Total other operating income	2,269	2,694

In 2022 and 2021, the Parent Company received a cash donation of PLN 2,000 thousand and PLN 1,000 thousand, respectively, from one of the Parent Company's shareholders. In the third quarter of 2021, the Group dissolved an allowance for receivables created in the first half of 2021 relating to a portion of subsidies classified as the Group's revenue in the CT-04 project in connection with the acceptance of the interim report and the resumption of the project's financing by the National Research and Development Center. The value of the released allowance for receivables amounted to PLN 1,131 thousand.

	01.01.2022	01.01.2021
OTHER OPERATING EXPENSES	-	-
	31.12.2022	31.12.2021
Loss on disposal of fixed assets	-	-
Revaluation of assets	-	1,131
Provision for the refund to the NCRD	-	4,658
Other	58	14
Total other operating expenses	58	5,804

In accordance with the principle of prudence, in the first half of 2021, the Group created an allowance for subsidy receivables in the amount of PLN 1,131 thousand. The aforementioned write-down relates to a portion of subsidies classified as the Group's revenue in the CT-04 project. In the third quarter of 2021, this write-down was reversed, which was recognized in other operating income. The Group in 2021 also established a provision for reimbursement to NCBiR in connection with the audit, which is described in Note 34 of this report. In connection with the settlement with NCBiR, the provision was used in 2022.

19. Financial income and costs

	01.01.2022	01.01.2021
FINANCIAL INCOME	-	-
	31.12.2022	31.12.2021
Interest income	3,127	-
Reversal of revaluation write-downs	-	-
Total financial income	3,127	-

The Group earned financial income in the current period as a result of investing free cash in short-term deposits and bonds.

	01.01.2022	01.01.2021
FINANCIAL COSTS/EXPENSES	-	-
	31.12.2022	1.12.2021
Interest expense on bank loans and borrowings received	-	27
Financial costs related to leasing agreements	321	373
Revaluation of investments	-	-
Excess negative exchange rate differences	78	56
Other	258	407
Total financial costs	657	863

The item Other in 2022 mainly presents the budget interest charged to the Group during the year, while in 2021 the item mainly includes the fee for the establishment of a registered pledge in the amount of PLN 400 thousand, which was used to secure a possible obligation to return the advance payment received by the Company.

20. Income tax

20.1 Tax expense

Due to the incurred tax losses the Group does not report any income tax expenses.

20.2 Reconciliation of the effective income tax rate

Reconciliation of income tax on the gross operating result before tax according to the statutory tax rate with income tax calculated accordingly to the effective income tax rate of the Group for the years ended 31December 2022 and 31December 2021 is as follows:

	01.01.2022	01.01.2021
EFFECTIVE INCOME TAX RATE	-	-
	31.12.2022	31.12.2021
Profit/(loss) before tax from continuing operations	-35,761	-32,572
Profit/(loss) before tax from discontinued operations	-	-
Profit/(loss) before tax	-35,761	-32,572

20.3 Deferred income tax

The Group has not recognised deferred income tax assets and liabilities taking into account the prudence principle. With no tax losses to be deducted, the impact of temporary differences is immaterial.

DEDUCTIBLE TEMPORARY DIFFERENCES, TAX LOSSES FOR WHICH DEFERRED INCOME TAX ASSETS HAVE NOT BEEN RECOGNISED IN THE STATEMENT OF FINANCIAL POSITION	Basis for asset recognition at the end of the period	Basis for asset recognition at the end of the period	Date of expiry of deductible temporary differences, tax losses
	31.12.2022	31.12.2021	
Due to:			
Provisions for employee benefits	618	479	-
Other reserves	1,166	5,795	-
Difference between leasing assets and liabilities	617	737	-
Tax losses	60,008	42,989*	2023-2027
Total:	62,409	43,726	

*the tax loss presented in the above table includes cumulative tax losses incurred by the Parent Company in 2018-2022.

21. Discontinued operations

There were no discontinued operations in the period of the 12 months of 2022 or the same comparative period.

22. Earnings per share

Basic earnings per share are calculated by dividing net profit for the period attributable to ordinary shareholders of the Parent Company by the number of issued ordinary shares outstanding at the end of the period.

Diluted earnings per share are calculated by dividing net profit for the period attributable to ordinary shareholders of the Parent Company (after deducting interest on redeemable preference shares convertible into ordinary shares) by the number of issued ordinary shares outstanding at the end of the period (adjusted for the effect of dilutive options and shares from probable future issues).

Below please find profit and share data used in the calculation of basic and diluted earnings per share:

	01.01.2022	01.01.2021
EARNINGS/LOSS PER SHARE	-	-
	31.12.2022	31.12.2021
Net profit attributable to ordinary shareholders of the Parent Company	-35,894	-32,572
Number of shares as at the balance sheet date used to calculate earnings per share	4,168,130	4,127,972
Number of shares as at the balance sheet date used to calculate diluted earnings per share	4,357,320	4,356,584
Earnings (loss) per share (in PLN)	-8.61	-7.89
Diluted earnings (loss) per share (in PLN)	-8.24	-7.48

23. Proposed profit distribution (coverage of loss) for the fiscal year

In 2022 the Parent Company recorded a negative financial result. The Management Board of the Parent Company proposes to cover the loss incurred in the current period by future profits.

24. Dividends paid and proposed to be paid

The Group did not pay any dividends in the current or previous period. No advances on dividends were paid either.

25. Expenditures on development work (in progress)

EXPENDITURES ON DEVELOPMENT WORK (IN PROGRESS)	31.12.2022	31.12.2021
Salaries	180	180
Write-off for impairment of capitalized expenditures	-	-
Total	180	180

The costs of development work of PLN 180 thousand were capitalized and shown in the consolidated statement of financial position under fixed assets as development work in progress, therefore they are not shown in the consolidated statement of performance and other comprehensive income.

26. Tangible fixed assets

TANGIBLE FIXED ASSETS	31.12.2022	31.12.2021
Owned	4,354	5,175
Used under a rental, lease or any other agreement, including a leasing agreement	6,312	7,437
Total	10,666	12,612

TANGIBLE FIXED ASSETS	31.12.2022	31.12.2021
Fixed assets, including:	10,666	12,612
buildings and structures	5,644	3,615
machinery and equipment	4,941	8,440
other fixed assets	81	557
Fixed assets under construction	-	-
Total	10,666	12,612

Included in machinery and equipment are medical and specialized equipment acquired and used by the Parent Company.

The decrease in the value of machinery and equipment reported as of the balance sheet date with respect to December 31, 2021 is due to the termination during the current period of some of the lease agreements for such assets.

LEASED FIXED ASSETS	31.12.2022			31.12.2021		
	Gross value	Depreciation	Net value	Gross value	Depreciation	Net value
Buildings and structures	13,103	7,576	5,527	9,040	5,557	3,483
Machines and equipment	10,443	9,659	785	15,606	11,651	3,955
Total	23,547	17,235	6,312	24,646	17,208	7,438

CHANGES IN FIXED ASSETS BY TYPE 01.01.2022 - 31.12.2022	Buildings and structures	Machinery and equipment	Other fixed assets	Total fixed assets
Gross fixed assets, beginning of period	9,771	24,852	702	35,326
Increases, due to	4,513	244	432	5,190
acquisitions	4,513	244	432	5,190
transfers from assets under construction	-	-	-	-
commencement of contract of lease	-	-	-	-
Decreases, due to	450	5,488	-	5,938
termination of rental agreement	-	5,488	-	5,488
disposals	450	-	-	450
Gross fixed assets, end of period	13,835	19,609	1,135	34,578
Accumulated depreciation, beginning of period	6,156	16,413	145	22,714
Increases, due to	2,484	3,463	909	6,856
Depreciation	2,484	3,463	909	6,856
Decreases, due to	450	5,208	-	5,658
termination of the rental agreement	-	5,208	-	5,208
disposals	450	-	-	450
Accumulated depreciation, end of period	8,190	14,668	1,053	23,912
Impairment losses, beginning of period	-	-	-	-
Increases, due to	-	-	-	-
impairment	-	-	-	-
Decreases, due to	-	-	-	-
reversal of impairment losses	-	-	-	-
Impairment losses, end of period	-	-	-	-
Net fixed assets, end of period	5,644	4,941	81	10,666

CHANGES IN FIXED ASSETS BY TYPE 01.01.2021 - 31.12.2021	buildings and structures	machinery and equipment	Other fixed assets	total fixed assets
Gross fixed assets, beginning of period	8,204	18,749	-	26,953
Increases, due to	1,567	7,303	702	9,572
acquisitions	1,567	7,303	702	9,572
transfers from assets under construction	-	-	-	-
commencement of contract of lease	-	-	-	-
Decreases, due to	-	1,200	-	1,200
termination of rental agreement	-	1,200	-	1,200
Gross fixed assets, end of period	9,771	24,852	702	35,326
Accumulated depreciation, beginning of period	3,622	11,134	-	14,756
Increases, due to	2,534	5,734	145	8,412
depreciation	2,534	5,734	145	8,412
Decreases, due to	-	454	-	454
termination of the rental agreement	-	454	-	454
Accumulated depreciation, end of period	6,156	16,413	145	22,714
Impairment losses, beginning of period	-	-	-	-
Increases, due to	-	-	-	-
impairments	-	-	-	-
Decreases, due to	-	-	-	-
reversal of impairment losses	-	-	-	-
Impairment losses, end of period	-	-	-	-
Net fixed assets, end of period	3,615	8,440	557	12,612

The Group does not have any property, plant and equipment which the Group's title thereto being restricted or serving as a security for liabilities except for leased or rented property, plant and equipment.

The Group has no contractual obligations to acquire property, plant and equipment in the future.

27. Intangible assets

The Group's intangible assets consist only of the Parent Company's intangible assets.

INTANGIBLES ASSETS	31.12.2022	31.12.2021
Owned	602	180
Used under a rental, lease or any other agreement, including a leasing agreement	-	-
Total	602	180

INTANGIBLES ASSETS	31.12.2022	31.12.2021
Acquired concessions, patents, licences and similar	602	180
Other intangible assets	-	-
Total	602	180

Reported intangible assets are mainly licenses and software used in the Group's operations.

CHANGES IN INTANGIBLE ASSETS 01.01.2022 - 31.12.2022	acquired concessions, patents, licences and similar	Total intangible assets
Gross intangible assets, beginning of period	596	596
Increases, due to	660	660
acquisitions	660	660
Decreases	-	-
Gross intangible assets, end of period	1,255	1,255
Accumulated depreciation, beginning of period	416	416
Increases, due to	238	238
Depreciation	238	238
Decreases	-	-
Accumulated depreciation, end of period	654	654
Impairment losses, beginning of period	-	-
Increases, due to	-	-
impairment	-	-
Decreases, due to	-	-
reversal of impairment losses	-	-
Impairment losses, end of period	-	-
Net intangible assets, end of period	602	602

CHANGES IN INTANGIBLE ASSETS 01.01.2021 - 31.12.2021	acquired concessions, patents, licences and similar	Total intangible assets
Gross intangible assets, beginning of period	427	427
Increases, due to	169	169
acquisitions	169	169
Decreases	-	-
Gross intangible assets, end of period	596	596
Accumulated depreciation, beginning of period	286	286
Increases, due to	129	129
Depreciation	129	129
Decreases	-	-
Accumulated depreciation, end of period	416	416
Impairment losses, beginning of period	-	-
Increases, due to	-	-
impairment	-	-
Decreases, due to	-	-
reversal of impairment losses	-	-
Impairment losses, end of period	-	-
Net intangible assets, end of period	180	180

The Group has no internally generated intangible assets.

The Group does not have any intangible assets with the Group's title thereto being restricted or serving as security for liabilities.

The Group has no contractual commitments to acquire intangible assets in the future.

28. Mergers of business entities, acquisitions of assets of significant value and acquisition of minority interests

There were no mergers of business entities, acquisitions of assets of significant value or acquisitions of minority interests to which the Parent Company or Subsidiary would be a party during 2022. As of 31 December 2022, there was no goodwill in the interim

condensed consolidated statement of financial position.

29. Other non-current assets

OTHER NON-CURRENT ASSETS	31.12.2022	31.12.2021
Non-current prepayments	-	1
Deposits	228	13
Total	228	14

The Group paid deposits in accordance with the executed lease agreements for space and laboratory equipment.

30. Trade and other receivables

TRADE RECEIVABLES	31.12.2022	31.12.2021
Net trade receivables	982	974
- from related parties	-	-
- from other undertakings	982	974
Write-downs on receivables	-	-
Gross trade receivables	982	974

TRADE RECEIVABLES	Total	Current	Overdue in days				
			<30 days	31-90 days	91-180 days	181-365 days	>366 days
31.12.2022							
- from related parties	-	-	-	-	-	-	-
- from other undertakings	982	926	2	5	49	-	-
Total gross trade receivables	982	926	2	5	49	-	-
31.12.2021							
- from related parties	-	-	-	-	-	-	-
- from other undertakings	974	972	-	2	-	-	-
Total gross trade receivables	974	972	-	2	-	-	-

OTHER RECEIVABLES	31.12.2022	31.12.2021
Other net receivables	8,696	10,732
Budgetary receivables	980	2,004
Receivables from grants	7,557	8,681
Other	159	47
Write-downs on receivables	-	-
Other gross receivables	8,696	10,732

Trade receivables are not interest bearing.

There are no overdue receivables not covered by allowances that would be considered uncollectible. In the opinion of the Parent Company's Management Board, there is no credit risk above the level determined by the allowance for uncollectible receivables specific to the Group's trade receivables.

Receivables from grants relate to eligible costs incurred in a given financial year and subject to reimbursement in subsequent reporting periods.

31. Other financial assets

OTHER FINANCIAL ASSETS	31.12.2022	31.12.2021
Short-term bonds	19,854	-
Loans granted	-	-
Write-downs	-	-
Other financial assets	19,854	-

The parent company invests in short-term corporate bonds as part of its free cash management.

32. Other assets

The Group makes prepaid expenses when they relate to advances for future services or supplies, the following table summarizes them.

ACCRUALS	31.12.2022	31.12.2021
Insurance policies	74	58
Down payments (licenses, domain names)	671	762
Other	12	86
Total	756	906

The Group has made the highest prepayments by purchasing licenses and domains, which are used during research projects.

33. Cash and cash equivalents

The balance of cash and cash equivalents shown in the consolidated cash flow statement consisted of the following items:

CASH AND CASH EQUIVALENTS	31.12.2022	31.12.2021
Cash in hand and bank accounts, including:	71,036	117,943
- cash on VAT accounts	-	-
Total	71,036	117,943

The Group has no restricted cash.

34. Equity

34.1 Share capital

As of 31 December 2022, the parent company's share capital (authorized capital) amounted to PLN 416,813.00 and was divided into 4,168,130 shares with a par value of PLN 0.10 each.

SHARE CAPITAL	31.12.2022	31.12.2021
Number of shares (pcs.)	4,168,130	4,127,972
Nominal value of shares (PLN)	0.10	0.10
Share capital	417	413

Changes in the share capital of the Parent Company:

On 12 May 2022, the registry court having jurisdiction over the Parent Company registered an amendment to the Parent Company's Articles of Association made on the basis of Resolution no. 2 of the Parent Company's Board of Directors, dated December 10, 2021, on the issue of 30,738 series K ordinary bearer shares, within the limits of the Parent Company's authorized capital, with the exclusion of the subscription rights of existing Parent Company shareholders in full (information provided in current report no. 17/2022, dated 12 May 2022).

On 7 September 2022, the registry court having jurisdiction over the Parent Company registered an amendment to the Parent Company's Articles of Association made pursuant to Resolution no. 2 of the Parent Company's Board of Directors dated 27 April 2022 on the issuance of the 9,420 series L ordinary bearer shares, within the limits of the Parent Company's authorized capital, excluding the pre-emptive rights of existing Parent Company shareholders in full (information provided in current report no. 13/2022 dated 27 April 2022). The shares were issued under the Parent Company's incentive program.

There were no changes in the share capital of the subsidiary in 2022.

The structure of share capital as of 31 December 2022 was as follows:

SHARE CAPITAL STRUCTURE				31.12.2022
Share series	Number of shares	Nominal value of shares	Preference rights	Number of votes
A	799,750	0,10	Yes	1,599,500
B	1,757,075	0,10	Not	1,757,075
C	82,449	0,10	Not	82,449
D	97,051	0,10	Not	97,051
E	347,643	0,10	Yes	695,286
F	26,925	0,10	Not	26,925
G	871,500	0,10	Not	871,500
H	52,354	0,10	Not	52,354
I	9,082	0,10	Not	9,082
J	84,143	0,10	Not	84,143
K	30,738	0,10	Not	30,738
L	9,420	0,10	Not	9,420
Total	4,168,130			5,315,523

34.1.1 Nominal value of shares

All outstanding shares have a nominal value of PLN 0.10 and are fully paid up.

34.1.2 Shareholder’s rights

Series A and E shares carry preference rights such that the holders of such shares are entitled to 2 votes per 1 share.

34.1.3 Shareholders with significant shareholding

The list of significant shareholders of the Parent Company (holding directly or indirectly through subsidiaries at least 5% of the total number of votes at the General Meeting) is presented in the table below.

Status as at the preparation of this consolidated financial statement:

SHARE CAPITAL OWNERSHIP STRUCTURE*

No.	Shareholder	Total number of shares	Total number of votes	Percentage share capital	Percentage of total votes at the GSM
1.	Michal Walczak	955,128	1,496,145	22.70%	27.93%
2.	Paul Holstinghausen Holsten	593,076	953,151	14.09%	17.80%
3.	Sylvain Cottens	340,897	526,730	8.10%	9.83%
4.	Funds Managed by Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. **.	303,075	303,075	7.20%	5.66%
5.	Other	2,016,973	2,077,441	47.92%	38.78%
	Total	4,209,149	5,356,542	100.00%	100.00%

**Based on information available to the Company.*

*** Of which Nationale-Nederlanden Otwarty Fundusz Emerytalny holds individually 271,564 shares in the Company, representing 5.07% of the total number of votes and 6.45% of the share capital.*

Status as of 31 December 2022:

SHARE CAPITAL OWNERSHIP STRUCTURE *

No.	Shareholder	Total number of shares	Total number of votes	Percentage share capital	Percentage of total votes at the GSM
1.	Michał Walczak	955,128	1,496,145	22.92%	28.15%
2.	Paul Holstinghausen Holsten	593,076	953,151	14.23%	17.93%
3.	Sylvain Cottens	340,897	526,730	8.18%	9.91%
4.	Funds Managed by Nationale-Nederlanden Powszechnie Towarzystwo Emerytalne S.A.**.	303,075	303,075	7.27%	5.70%
5.	Other	1,975,954	2,036,422	47.41%	38.31%
Total		4,168,130	5,315,523	100.00%	100.00%

*Based on information available to the Company.

** Of which the Nationale-Nederlanden Open Pension Fund individually holds 271,564 shares in the Company, representing a 5.11% share in the total number of votes and a 6.52% share in the share capital.

34.2 Share premium reserve

The Group's share premium reserve is equal to the Parent Company's share premium reserve and results from the following items:

SHARE PREMIUM RESERVE	31.12.2022	31.12.2021
Issuance of series B AGIO shares	3,774	3,774
Voluntary capital reduction without consideration	36	36
Issuance of C series AGIO shares investment agreements 2018	3,898	3,898
Issuance of series C2 and D AGIO investment agreements 2019	8,584	8,584
Issuance of G, H, I, J, K, L	153,739	153,739
Total	170,031	170,031

34.3 Reserve capital

The Group’s reserve capital is equal to the Parent Company’s reserve capital and arises from the following items:

OTHER CAPITAL RESERVES	31.12.2022	31.12.2021
Redemption of shares	103	103
Actuarial gains and losses	72	72
Unregistered share issue	-	-
Total	175	175

34.4 Share-based payment reserve

The share-based payment reserve consist of the valuation of the incentive scheme in the Company. The description of the incentive scheme is included in Note 15.21.

35. Retirement benefit obligations and provisions for liabilities

PROVISIONS FOR EMPLOYEE BENEFITS	31.12.2022	31.12.2021
Provision for outstanding holiday entitlement	543	441
Provison for pensions	75	59
Total, including:	618	501
- long-term	51	33
- short-term	567	467

The provision for outstanding holiday entitlement is presented in the consolidated statement of financial position in short-term, in the item provisions for liabilities.

CHANGE IN EMPLOYEE PROVISIONS	Provision for outstanding holiday entitlement	Provision for pensions	Total
Status as of 01.01.2022	441	59	501
Creation of provision	124	16	139
Costs of benefits paid (use)	-	-	-
Provisions released	22	-	22
Status as of 31.12.2022	543	75	618
Status as of 01.01.2021	278	66	344
Creation of provision	163	11	174
Costs of benefits paid (use)	-	-	-
Provisions released	-	18	18
Status as of 31.12.2021	441	59	501
PROVISIONS FOR LIABILITIES		31.12.2022	31.12.2021
External services		94	137
Other		1,072	5,658
Total other reserves		1,166	5,795

In connection with the fact that the Parent Company became aware of the proceedings conducted by the state authorities concerning potential irregularities in carrying out public procurement procedures as part of EU projects, the Parent Company appointed external, reputable financial and legal advisors to conduct an audit. As a result, as of 31 December 2021, the Parent Company created a provision for reimbursement of part of the funds received from NCBiR in the amount of PLN 4,658 thousand (which amount includes the principal amount of PLN 3,891 thousand and interest in the amount of PLN 767 thousand). In addition, the Group established a provision for audit costs and preparation of legal strategy in the amount of PLN 1,000 thousand.

Based on the results of the audit, on 13 April 2022, the Group reimbursed NCBR in the amount of PLN 4,658 thousand (reimbursement to NCBR of PLN 3,891 thousand of the dofinancing received to date and PLN 767 thousand of interest accrued as of the date of the reimbursement). On 16 November 2022. The Parent Company received letters from NCBiR regarding the final settlement of the audit results. As indicated by NCBiR, the Group additionally reimbursed a lump sum (indirect costs) on these expenses in the total amount of PLN 803 thousand, together with statutory interest in the amount of PLN 229 thousand.

Other provisions as of 31 December 2022, in the amount of PLN 1,000 thousand, mainly relate to the payment of planned bonuses and a potential cost related to withholding tax withheld by a Japanese contractor.

Other provisions for third-party services mainly relate to the audit of the financial statements by the auditing firm.

CHANGE IN PROVISIONS FOR LIABILITIES	External services	Other	Total
Status as of 01.01.2022	137	5,658	5,795
Creation of reserves	94	1,072	1,166
Use of provision	137	5,658	5,795
Release of provision	-	-	-
Status as of 31.12.2022	94	1,072	1,166

CHANGE IN PROVISIONS FOR LIABILITIES	External services	Other	Total
Status as of 01.01.2021	416	-	416
Creation of reserves	148	5,658	5,806
Use of provision	427	-	427
Release of provision	-	-	-
Status as of 31.12.2021	137	5,658	5,795

36. Loans received

The Group does not report liabilities for loans received.

LOANS AND BORROWINGS	31.12.2022	31.12.2021
Loans received	-	-
Total, including:	-	-
- long-term	-	-
- short-term	-	-

37. Lease liabilities

Structure of lease liabilities by maturity

LEASE LIABILITIES	31.12.2022	31.12.2021
Short-term lease liabilities, including:	3,717	5,241
- up to 1 month	450	545
- from 1 month to 3 months	855	1,066
- from 3 months to 6 months	1,059	1,591
- from 6 months to 1 year	1,353	2,039
Long-term leasing liabilities, including:	3,235	2,940
- from one to five years	3,235	2,940
- more than five years	-	-
Total	6,952	8,181

Lease liabilities mainly relate to leases of office space, laboratory space and specialized equipment used in the Group's day-to-day operations.

38. Trade and other liabilities (short-term)

Liabilities declared in the consolidated statement of financial position are for the most part payable within 30-90 of the debit document. The declared liabilities do not include settlements related to loans, borrowings and lease liabilities.

TRADE LIABILITIES	31.12.2022	31.12.2021
- to related parties	-	-
- to other entities	5,648	3,193
Total	5,648	3,193

OTHER SHORT-TERM LIABILITIES	31.12.2022	31.12.2021
Tax, customs, insurance and other benefits liabilities	1,349	896
Payroll liabilities	815	647
Other	5	3
Total	2,169	1,545

39. Other liabilities/deferred income

The Group has deferred income, which relates to grant advances received by the Parent Company. These funds will be used to cover the corresponding costs in the next reporting period. The value of advances received and unused at the balance sheet date is as follows:

DEFERRED INCOME	31.12.2022	31.12.2021
- project POIR.01.02.00-00-0073/18	-	-
- project POIR.01.01.01-00-0956/17	-	-
- project POIR.04.01.04-00-0116/16	-	-
- project POIR.01.01.01-00-0931/19	-	-
- project POIR.01.01.01-00-0747/16	-	-
- project POIR.01.01.01-00-0740/19	-	-
- project POIR.01.01.01-00-0741/19	-	-
- project POIR.04.01.02-00-0147/16	126	126
- project POIR.01.02.00-00-0079/18	-	-
Other	-	-
Total	126	126

There are no accrued expenses in the Group.

40. Contingent liabilities

The Company issues registered blank promissory notes for each grant agreement (for each project). This is required by the regulations for projects co-financed from public funds.

As collateral for proper performance of obligations under the project financing agreement, the Parent Company's Management Board submitted security in the form of a blank promissory note bearing the clause "not to order." The security was established until the end of the projects' durability period. This is a requirement resulting from the subsidy (grant) agreement. Such a provision is included in each of the agreements to which the Parent Company is a party.

The Company has also issued blank promissory notes related to lease agreements for laboratory equipment. The lessor is authorised to fill these promissory notes up to the amount equivalent to all due but unpaid receivables due to the lessor under the lease agreements.

CONTINGENT LIABILITIES			31.12.2022
Type of contract to be secured		Promissory note together with a promissory note agreement	
Description	Contractual amount	Potential contingent liability	Type of promissory note
POIR.01.01.01-00-0747/16	24,320	12,027	blank
POIR.01.01.01-00-0956/17	27,683	16,884	blank
POIR.01.02.00-00-0073/18	25,511	11,760	blank
POIR.01.02.00-00-0079/18	29,558	14,036	blank
POIR:01.01.01-00-0740/19	28,960	12,000	blank
POIR.01.01.01-00-0931/19	7,759	4,968	blank
POIR.01.01.01-00-0741/19	27,411	5,120	blank
Lease contract no. 18/015253	2,839	299	blank
Lease contract no 18/007516	598	17	blank
Lease contract no o. 18/021031	496	71	blank
Total	175,135	77,183	

41. Litigation

As of December 31, 2022 and as of the date of these consolidated financial statement, the Group entities are not party to any litigation.

42. Tax settlements

Tax settlements as well as other areas of business subject to legal regulations (among other customs or foreign exchange related matters) may be inspected by administrative bodies authorized to impose penalties and sanctions. However, the legal system in force is not perfect, it has gaps and axiological and logical inconsistencies. This applies both to law-making and application of law. Instability and ambiguity of many provisions of law results in discrepancies in their interpretation, which in turn translates into different views of the tax authorities and entrepreneurs.

Tax settlements may be inspected. As a result of such inspections tax settlements of the entities comprising the Group may be increased by additional tax liabilities. In the opinion of the Management Board of the Parent Company as of 31 December 2022 and as of 31 December 2021 it was not necessary to create any provisions for recognizable and quantifiable tax risk.

43. Explanations to the cash flow statement

CASH AT THE END OF THE PERIOD	31.12.2022	31.12.2021
Cash in the statement of financial position	71,036	117,943
Cash in the cash flow statement	71,036	117,943
SPECIFICATION	31.12.2022	31.12.2021
Depreciation:	7,094	7,355
amortization of intangible assets	238	129
depreciation of property, plant and equipment	6,856	7,226
Foreign exchange gains (losses)	-112	36
accrued exchange differences	-112	36
Interest:	-2,574	409
other interest paid	256	-
other accrued interest	-32	-
Interest received on bonds	-528	-
interest accrued on loans received	-1	-
Interest received on short-term deposits	-2,401	-
accrued interest on bonds	-188	-
interest paid on leasing	321	409
Change in reserves:	-4,512	5,536
balance sheet change in provisions for trade liabilities	-4,651	5,379
balance sheet change in provisions for employee benefits	139	157
Change in receivables:	1,529	-9,876
change in short-term receivables as per balance sheet	1,528	-9,877
change in long-term receivables as per balance sheet	1	1
Change in short-term liabilities, except for financial liabilities:	3,364	-8,788
change in short-term liabilities as per the balance sheet	3,364	1,486
change in other liabilities	-	-10,274
Change in accruals:	-150	-68
Change in prepayments and accrued income as per the balance sheet	-150	-68

44. Information on related parties

The following is a list of related parties to the Group as of 31 December 2022, with which the Group transacted during the period covered by this financial statement.

Entity or individual	Function held / description of relationship
Sylvain Cottens	Member of the Management Board of Captor Therapeutics GmbH, shareholder of Captor Therapeutics S.A.
Thomas Shepherd	President of the Management Board of Captor Therapeutics S.A
Michał Walczak	President of the Management Board of Captor Therapeutics GmbH, Member of the Management Board of Captor Therapeutics S.A., shareholder of Captor Therapeutics S.A.
Radosław Krawczyk	Member of the Management Board of Directors of Captor Therapeutics S.A.
Captor Therapeutics GmbH	Company in witch 100% of shares are held by Captor Therapeutics S.A.
Paweł Holstinghausen Holsten	Member of the Supervisory Board of Captor Therapeutics S.A., shareholder of Captor Therapeutics S.A.
Maciej Wróblewski	Member of the Supervisory Board of Captor Therapeutics S.A.
Florent Gros	Member of the Supervisory Board of Captor Therapeutics S.A.
Krzysztof Samotij	Member of the Supervisory Board of Captor Therapeutics S.A.
Swissvention Partners GMBH	Company in which Florent Gros is the owner and managing director
Robert Florczykowski	Member of the Supervisory Board of Captor Therapeutics S.A. from 5 January 2022

Transactions with related parties

The table below presents transactions executed in the current period with entities related to the Group.

01.01.2022 -	Towards subsidiaries	Towards jointly- owned subsidiaries	Towards key management*	Towards other related parties**
31.12.2022				
Purchases	-	-	-	-
Sales	-	-	-	-
Loans granted	-	-	-	-
Financial income - interest on loans	-	-	-	-
Loans received	-	-	-	-
Financial costs - interest on loans and remuneration for the establishment of a registered pledge	-	-	-	-
Trade receivables	-	-	-	-
Trade payables	-	-	-	-
Remuneration – paid by the Company	-	-	3,104	79
Other	-	-	-	-

* this item includes persons having with authority and responsibility for planning, directing and controlling the activities of the entity

** this item includes entities related through key management

Transactions between related parties took place on terms equivalent to those applicable to transactions concluded at arm's length.

44.1 Parent company of the entire Group

Captor Therapeutics S.A. is the parent company in the Group.

44.2 Entity having a significant influence of the Group

There is no entity having a significant influence of the Captor Therapeutics S.A. Group.

45. Salaries, bonuses and benefits for members of governing bodies

GROSS SALARIES	31.12.2022		31.12.2021	
	paid	payable	Paid	payable
Management Board of the Parent Company	1,998	2,033	3,096	3,096
Supervisory Board of the Parent Company	326	355	298	27
Total	2,324	2,388	3,394	3,123

The above table presents the total values of due remuneration of all members of the Parent Company's Management Board and Supervisory Board, broken down for 2022 and 2021. The difference between the values in the due and paid column presents the Group's liability as of the respective balance sheet date for unpaid but due remuneration for members of the Parent Company's bodies.

45.1 Participation of senior management (including members of the Management Board and Supervisory Board) in the employee share programme

The Incentive Program was established pursuant to Resolution no. 14 of the Parent Company's Annual General Meeting of 16 May 2019, as amended by Resolution No. 22 of the Parent Company's Annual General Meeting of 26 June 2020 and Resolution no. 10 of the Parent Company's Extraordinary General Meeting of 8 January 2021. Pursuant to the Incentive Program, eligible persons (i.e., persons employed by the Parent Company or its subsidiaries, under an employment contract or other legal basis, designated by the Parent Company's Management Board after obtaining the approval of the Supervisory Board, as well as members of the Supervisory Board designated by the General Meeting) will have the right to purchase existing or newly issued shares in the Parent Company. The decision as to whether the Parent Company will offer employees the treasury shares acquired by the Parent Company from the Parent Company's shareholders (primary commitment) or issue newly issued shares (so-called alternate authorization) has been left to the Parent Company.

As of the date of this consolidated financial statement, members of the Parent Company's Management Board and Supervisory Board have entered into an incentive program participation agreement entitling them to shares granted under the Incentive Program:

- Radosław Krawczyk – Member of the Management Board, Chief Financial Officer of the Parent Company, executed an agreement for participation in the incentive scheme entitling her to subscribe for 5,816 ordinary shares of the Parent Company; and
- Thomas Shepherd – Member of the Management Board of, President of the Management Board of the Parent Company, executed an agreement for participation in the incentive scheme entitling him to subscribe for 77,772 ordinary shares Parent Company;
- Paweł Holstinghausen Holsten - Member of the Parent Company's Supervisory Board, executed an agreement for participation in the incentive scheme entitling him to subscribe for 12,443 ordinary shares Parent Company;
- Florent Gros-Member - Member of the Parent Company's Supervisory Board, executed an agreement for participation in the incentive scheme entitling him to subscribe for 12,443 ordinary shares Parent Company;
- Krzysztof Samotij-Member - Member of the Parent Company's Supervisory Board, executed an agreement for participation in the incentive scheme entitling him to subscribe for 12,443 ordinary shares Parent Company;
- Maciej Wróblewski-Member - Member of the Parent Company's Supervisory Board, executed an agreement for participation in the incentive scheme entitling him to subscribe for 12,443 ordinary shares Parent Company.

Captor Therapeutics' share ownership in the incentive program by executives as of the date of the report is presented below:

Shareholder	Number of shares
Management	
Thomas Shepherd	38,886
Radosław Krawczyk	2,954
Supervisory Board	
Paweł Holstinghausen Holsten	3,110
Florent Gros	3,110
Krzysztof Samotij	3,110
Maciej Wróblewski	3,110

46. Auditor firm’s fee

AUDITOR FIRM’S FEE	31.12.2022	31.12.2021
Audit of annual separate and consolidated financial statements	80	80
Review of interim separate and consolidated financial statements	41	42
Audit services related to IPO	-	60
Other services	10	-
Total	131	182

47. Purposes and principles of financial risk management

Cash and subsidies are the main financial instruments used by the Group. The main purpose of such financial instruments is to obtain funds for the Group’s activity. The Group also has other financial instruments, such as trade receivables and payables, which arise directly in the course of its operations.

The main types of risk arising from Group’s financial instruments include the interest rate risk, foreign exchange risk, risk related to liquidity and credit risk. The Management Board of the Parent Company verifies and coordinates the principles of management of each of such risk types – such principles are briefly described below.

47.1 Interest rate risk

The Group’s exposure to the risk related to changes in interest rates concerns mainly long-term financial liabilities.

The Group manages interest expenses by incurring liabilities with variable interest rate. The Group gathers and analyses current market information about the present exposure to a change of the applicable interest rate.

Uncertainty over future interest rates, and consequently amounts of future financial expenses constitutes a significant obstacle in the investment decision making process.

The main purpose of the interest rate risk management is to hedge interest expenses against the increase thereof as a result of a rise in interest rates. The possibilities of hedging the interest rate risk are analysed and assessed by the Group depending on the current needs. The Group has not entered into any interest rate hedging contracts. In the period covered by this consolidated financial statement the Group was not a party to any hedging transactions, and in particular it did not purchase any derivative

instruments to hedge the interest rate risk.

47.2 Foreign exchange risk

Due to the cooperation with a foreign contract partner and international suppliers of services, in 2022 the Group was exposed to foreign exchange risk affecting mainly trade receivables in EUR and trade payables in: EUR, USD and CHF.

As a result of valuation of receivables and payables expressed in foreign currencies, carried out as of the balance sheet date, and as a result of current settlements in foreign currencies, certain positive and negative foreign exchange differences arise. Their values fluctuate throughout the year which is caused by changes in exchange rates.

For EUR/PLN exchange rate there is a partial natural hedging due to the fact that revenues under contracts with a client in EUR are partially offset by the costs in the same currency. The Group gathers and analyses current market information on the present exposure to foreign exchange risks. The main purpose of the foreign exchange risk management is to hedge negative exchange differences against their increase as a result of depreciation of the domestic currency. The possibilities of hedging the foreign exchange risk are analysed and assessed by the Group depending on the current needs. Due to currency fluctuations in 2022 the company did not enter into any foreign exchange risk hedging transactions.

47.3 Risk related to prices of products and goods

The Group presently conducts research and development activity, and therefore does not earn significant revenue from its core activities, but contracts it signs protect itself against price increases by using standard provisions for price changes based on the inflation rate. With regard to purchased services and goods, the Group uses a commercial negotiation policy to negotiate prices in view of the prevailing global inflationary trend.

47.4 Credit risk

Taking into consideration that at this stage of development the Group does not conduct any commercial activity, the credit risk is immaterial.

47.5 Risk related to liquidity

The Group is monitoring the risk of the lack of funding using a periodic liquidity planning tool. The tool takes into account maturity dates of both investments and financial assets (e.g. accounts receivable, other financial assets) and projected cash flows from operating activities.

The purpose of the Group is to maintain balance between the financing continuity and flexibility by using various sources of financing.

The table below presents the Group’s financial liabilities as of 31 December 2022 by maturity date, based on contractual non-discounted payments.

31.12.2022	On demamd	Less than 3 months	Between 3 and 12 months	Between 1 and 5 years	More than 5 years	Total
Interest-bearing bank loans and borrowings	-	-	-	-	-	-
Leasing liabilities	-	1,365	2,545	3,397	-	7,307
Trade and other liabilities	562	6,947	307	-	-	7,817
Total	562	8,312	2,853	3,397	-	15,124

48. Financial instruments

Fair values of particular classes of financial instruments

The following table provides a comparison of the carrying amounts and fair values of all of the Group's financial instruments, by class and category of assets and liabilities.

FAIR VALUES OF PARTICULAR CLASSES OF FINANCIAL ASSETS AND LIABILITIES	Category	Carrying amount		Fair value	
		31.12.2022	31.12.2021	31.12.2022	31.12.2021
Financial assets					
Bonds	WwgZK	19,854	-	19,854	-
Loans granted	WwgZK	-	-	-	-
Trade receivables	WwgZK	982	974	982	974
Other receivables	WwgZK	8,696	10,732	8,696	10,732
Cash and cash equivalents	WwgZK	71,036	117,943	71,036	117,943
Total		100,568	129,649	100,568	129,649
Financial liabilities					
Interest-bearing bank loans and borrowings	PZFwgZK	-	-	-	-
Leasing liabilities	According to MSSF16	6,952	8,181	6,952	8,181
Trade payables	PZFwgZK	5,648	3,193	5,648	3,193
Other liabilities	PZFwgZK	2,169	1,545	2,169	1,545
Total		14,768	12,919	14,768	12,919

Abbreviations used:

WwgZK - Measured at amortised cost

PZFwgZK - Other financial liabilities measured at amortised cost

The lease liabilities presented in the table above are measured in accordance with IFRS 16 'Leases'.

The fair value of financial instruments held by the Group as at the balance sheet date does not differ from the value presented in the consolidated financial statement due to the fact that in relation to short-term instruments the discount effect, if any, is not significant, as these instruments relate to transactions concluded on market terms

49. Security instruments established on assets

The Group does not have security instruments established on assets.

50. Equity management

The main purposes of the Group’s equity management is to maintain good credit rating and safe equity indicators which would support the Group’s operating activity and increase the value for its shareholders.

The Group manages the capital structure and makes changes thereto as a result of any changes of economic conditions. In order to maintain and adjust the capital structure the Group may change payments of dividends to shareholders, return equity to shareholders (e.g. through repurchase of own shares in order to redeem them) or issue new shares. In the reporting period no changes in purposes, principles and processes applicable is this area were made.

The Group monitors its capitals by applying a leverage ratio which is calculated as the ratio of the net debt to the sum of capital increased by net debt. The Group’s principles state that such ratio cannot be greater than 50%. In the net debt the Group includes interest-bearing bank loans and borrowings, trade and other liabilities, minus cash and cash equivalents.

EQUITY MANAGEMENT	31.12.2022	31.12.2021
Interest-bearing loans and borrowings	-	-
Leasing liabilities	6,952	8,181
Trade and other liabilities	9,727	11,160
Less cash and cash equivalents	-71,036	-117,943
Net debt	-54,357	-98,602
Equity	96,322	124,201
Net equity and debt	41,964	25,599
Leverage ratio (%)	-130%	-385%
Leverage ratio (%) without cash for investments	-130%	-385%

51. Structure of employment

The structure of average employment in the Group at the end of each period was as follows (in persons):

STRUCTURE OF EMPLOYMENT	31.12.2022	31.12.2021
Number of persons employed by the Company	110	97
Number of persons employed in the Capital Group	111	98

52. Seasonality

There is no seasonality or cyclicity in the business segment in which the Group companies operate.

53. Events after the balance sheet date

The following significant events occurred after the balance sheet date (i.e. 31 December 2022) that may affect the assessment of the financial position of the Captor Therapeutics S.A. Group:

- Announcement of strategic plans of Captor Therapeutics S.A. for 2023-2025

On 6 March 2023, the Company’s Supervisory Board adopted a resolution to approve the next steps in the Company’s strategy for 2023-2025 (“Strategic Plans”) presented by the Management Board. The key objectives of the Company’s Strategic Plans are described in Section 3.3.3 of this Report and in Current Report No. 7/2023 of 6 March 2023.

The Parent's Management plans to secure funding for the implementation of the adopted Strategic Plans by issuing (within the authorized capital) up to 1,222,467 ordinary shares of the Company. The shares will be issued at the time that is considered most advantageous for the Company, taking into account market conditions and investor interest, although the Management Board does not rule out issuing a smaller number of shares if the issue price enables the Company to raise financing enabling the implementation of the Strategic Plans.

On April 3, 2023. The Extraordinary General Meeting of Shareholders passed a resolution to increase the Parent Company's share capital within the framework of authorized capital (information provided in current report No. 13/2023 dated April 3, 2023).

- Registration of a share capital increase and amendments to the Articles of Association

After the end of the reporting period, i.e. on 10 February 2023, the court of registration with jurisdiction over the Company registered an amendment to the Company’s Articles of Association made by Resolution No. 2 adopted by the Company’s Management Board on 28 September 2022, to issue 41,019 Series M ordinary bearer shares within the limits of the Company’s authorized capital, excluding pre-emptive rights of the Company’s existing shareholders in full (the Company disclosed the adoption of the resolution in on 28 September 2022, in Current Report No. 37/2022). The shares were issued as part of the incentive plan in effect in the Company. Information provided in Current Report No. 2/2023 of 10 February 2023.

- Registration of Series M ordinary bearer shares with the securities depository and admission and introduction of Series M shares to trading

On 10 March 2023, the Central Securities Depository of Poland (“KDPW”) issued a release on the registration with the securities depository of 41,019 Series M ordinary bearer shares (“Shares”). On 14 March 2023, the Shares were registered with the KDPW securities depository with the ISIN code PLCPTRT00014.

On 9 March 2023, the Management Board of the Warsaw Stock Exchange adopted Resolution No. 198/2023 on the introduction to exchange trading on the primary market as of 14 March 2023 of 41,019 Series M common bearer shares of the Company with a par value of PLN 0.10 each, on the condition that, on 14 March 2023, the Central Securities Depository of Poland registered these shares and marked them with the ISIN code PLCPTRT00014. Information provided in Current Reports No. 5/2023 of 2 March 2023, No. 9/2023 of 9 March 2023 and No. 10/2023 of 13 March 2023.

– Resolution of the Management Board of the Company on a share issue within the limits of the authorized share capital

On 14 February 2023, the Company’s Management Board adopted a resolution to issue 11,292 Series N common bearer shares within the limits of the Company’s authorized capital, while fully excluding the pre-emptive rights of the Company’s existing shareholders.

The share issue is related to the implementation of the Company’s share-based incentive program for employees and members of its corporate bodies.

– Publish information on R&D progress and disclosure of molecular targets in projects CT-01, CT-02 and CT-05.

On March 27, 2023, the Company disclosed the molecular targets in the CT-01, CT-02 and CT-05 projects and provided information on the progress of CT-01 R&D. Details are described in Current Report No. 12/2023.

54. COVID-19 pandemic

In connection with the ongoing pandemic of the coronavirus SARC-Cov2, which causes COVID-19 disease worldwide, the following factors have been identified as at the date of these financial statements, which may temporarily affect the extension of the period of individual research work in ongoing research and development projects and/or the financial situation of the Group and the Company.

In the event that new restrictions and limitations in the economies of the countries affected by the pandemic persist or are introduced, as well as uncertainty about developments in the capital markets:

- there may be delays in the supply of materials and reagents from contractors with operations or collaborations in affected countries;
- research work by certain highly specialised external service providers working with the Group may be delayed, postponed or unable to be contracted due to staffing constraints or inability to commit based on the extremely high uncertainty index, restrictions in place;
- it may be necessary to quarantine one or more or all employees working in the research or laboratory teams as well as other personnel.

At the date of preparation of this consolidated financial statement the Management Board of the Parent Company was not able to estimate the possible scale of the effects of potential economic risks. The Parent Company monitors on an ongoing basis the development of the situation affecting the likelihood of the effects of potential risks. As at the date of these financial statements, the coronavirus pandemic has not adversely affected the ability of the Group and the Company to continue as a going concern. The Management Board of the Parent Company has introduced a number of measures to increase safety at work and measures to eliminate potential risks associated with its operations. Measures to enhance occupational safety and eliminate risks associated with operations have also been implemented at the Subsidiary.

55. War in Ukraine

In connection with the outbreak of the armed conflict between Ukraine and Russia, the Company analysed the impact of the current situation on the Group’s operations. In the Management Board’s opinion there are no material risks which may significantly affect the activities being conducted. The Group does not either have any assets in Ukraine or conduct any activities within the areas affected by the conflict.

As a result of military operations conducted by Russia, the EU countries and the USA introduced a number of severe sanctions on Russia which cover key sectors of the Russian economy through blocking access to technologies and markets, including financial markets. In view of the foregoing it cannot be excluded that the implemented sanctions package may affect the activities conducted by the Company, including those in Poland, for example due to deliveries of raw materials from Russia. Also, deliveries of materials from Ukraine may be significantly disturbed or even stopped, which may consequently disrupt the global supply chain.

Further, the armed conflict in Ukraine may affect the macroeconomic situation in Poland, and in particular interest rates and valuation of Polish currency (Polish zloty). The foreign exchange risk may result in the increase of the costs of servicing liabilities related to research services and reagents purchased abroad. As of the date of preparation of this report the Management Board of the Company is not able to determine the exact impact of such events on the research programs being conducted or availability of funding. The Company is analysing the situation on an ongoing basis and the Management Board of the Company will keep you updated of any new circumstances affecting the financial results and business situation of the Group.

Signatures:

Person entrusted with keeping the books of account of the Company: Małgorzata Puterko – ABAK S.A.

Thomas Shepherd	Michal Jerzy Walczak	Radoslaw Krawczyk
Signed with an electronic signature	Signed with an electronic signature	Signed with an electronic signature
President of the Management Board	Member of the Management Board Chief Scientific Officer	Member of the Management Board Chief Financial Officer